


22nd Edition

# CURRENT

Diagnosis & Treatment



# Pediatrics

WILLIAM W. HAY JR. | MYRON J. LEVIN  
ROBIN R. DETERDING | MARK J. ABZUG

Mc  
Graw  
Hill  
Education

**LANGGE**<sup>®</sup>

a LANGE medical book

# CURRENT

# Diagnosis & Treatment

# Pediatrics

TWENTY-SECOND EDITION

Edited by

**William W. Hay, Jr., MD**

Professor, Department of Pediatrics  
Section of Neonatology and the Division of Perinatal  
Medicine  
University of Colorado School of Medicine and  
Children's Hospital Colorado

**Myron J. Levin, MD**

Professor, Departments of Pediatrics and Medicine  
Section of Pediatric Infectious Diseases  
University of Colorado School of Medicine and  
Children's Hospital Colorado

**Robin R. Deterding, MD**

Professor, Department of Pediatrics  
Section of Pediatric Pulmonary Medicine  
University of Colorado School of Medicine and  
Children's Hospital Colorado  
Medical Director, Breathing Institute  
Children's Hospital Colorado

**Mark J. Abzug, MD**

Professor, Department of Pediatrics  
Section of Pediatric Infectious Diseases  
Associate Vice Chair for Academic Affairs,  
Department of Pediatrics  
University of Colorado School of Medicine and  
Children's Hospital Colorado

*and Associate Authors*

The Department of Pediatrics at the University of Colorado School of Medicine  
is affiliated with Children's Hospital Colorado.



Medical

New York Chicago San Francisco Athens London Madrid Mexico City Milan  
New Delhi Singapore Sydney Toronto

Copyright © 2014 by McGraw-Hill Education. All rights reserved. Except as permitted under the United States Copyright Act of 1976, no part of this publication may be reproduced or distributed in any form or by any means, or stored in a database or retrieval system, without the prior written permission of the publisher.

ISBN: 978-0-07-182735-5

MHID: 0-07-182735-8

The material in this eBook also appears in the print version of this title: ISBN: 978-0-07-182734-8,  
MHID: 0-07-182734-X.

eBook conversion by codeMantra  
Version 2.0

All trademarks are trademarks of their respective owners. Rather than put a trademark symbol after every occurrence of a trademarked name, we use names in an editorial fashion only, and to the benefit of the trademark owner, with no intention of infringement of the trademark. Where such designations appear in this book, they have been printed with initial caps.

McGraw-Hill Education eBooks are available at special quantity discounts to use as premiums and sales promotions or for use in corporate training programs. To contact a representative, please visit the Contact Us page at [www.mhprofessional.com](http://www.mhprofessional.com).

Previous editions copyright © 2012, 2011, 2009, 2007, 2003, 2001 by The McGraw-Hill Companies, Inc., and copyright © 1999, 1997, 1995, 1991, 1987 by Appleton & Lange.

#### Notice

Medicine is an ever-changing science. As new research and clinical experience broaden our knowledge, changes in treatment and drug therapy are required. The authors and the publisher of this work have checked with sources believed to be reliable in their efforts to provide information that is complete and generally in accord with the standards accepted at the time of publication. However, in view of the possibility of human error or changes in medical sciences, neither the authors nor the publisher nor any other party who has been involved in the preparation or publication of this work warrants that the information contained herein is in every respect accurate or complete, and they disclaim all responsibility for any errors or omissions or for the results obtained from use of the information contained in this work. Readers are encouraged to confirm the information contained herein with other sources. For example and in particular, readers are advised to check the product information sheet included in the package of each drug they plan to administer to be certain that the information contained in this work is accurate and that changes have not been made in the recommended dose or in the contraindications for administration. This recommendation is of particular importance in connection with new or infrequently used drugs.

#### TERMS OF USE

This is a copyrighted work and McGraw-Hill Education and its licensors reserve all rights in and to the work. Use of this work is subject to these terms. Except as permitted under the Copyright Act of 1976 and the right to store and retrieve one copy of the work, you may not decompile, disassemble, reverse engineer, reproduce, modify, create derivative works based upon, transmit, distribute, disseminate, sell, publish or sublicense the work or any part of it without McGraw-Hill Education's prior consent. You may use the work for your own noncommercial and personal use; any other use of the work is strictly prohibited. Your right to use the work may be terminated if you fail to comply with these terms.

THE WORK IS PROVIDED "AS IS." MCGRAW-HILL EDUCATION AND ITS LICENSORS MAKE NO GUARANTEES OR WARRANTIES AS TO THE ACCURACY, ADEQUACY OR COMPLETENESS OF OR RESULTS TO BE OBTAINED FROM USING THE WORK, INCLUDING ANY INFORMATION THAT CAN BE ACCESSED THROUGH THE WORK VIA HYPERLINK OR OTHERWISE, AND EXPRESSLY DISCLAIM ANY WARRANTY, EXPRESS OR IMPLIED, INCLUDING BUT NOT LIMITED TO IMPLIED WARRANTIES OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. McGraw-Hill Education and its licensors do not warrant or guarantee that the functions contained in the work will meet your requirements or that its operation will be uninterrupted or error free. Neither McGraw-Hill Education nor its licensors shall be liable to you or anyone else for any inaccuracy, error or omission, regardless of cause, in the work or for any damages resulting therefrom. McGraw-Hill Education has no responsibility for the content of any information accessed through the work. Under no circumstances shall McGraw-Hill Education and/or its licensors be liable for any indirect, incidental, special, punitive, consequential or similar damages that result from the use of or inability to use the work, even if any of them has been advised of the possibility of such damages. This limitation of liability shall apply to any claim or cause whatsoever whether such claim or cause arises in contract, tort or otherwise.

# Contents

|   |          |  |           |
|---|----------|--|-----------|
| Authors   | xix      | Abdominal Wall Defects   | 56        |
| Preface   | xxvii    | Diaphragmatic Hernia   | 56        |
| <b>1. Advancing the Quality and Safety of Care</b>  | <b>1</b> | Gastrointestinal Bleeding  | 57        |
| <i>Daniel Hyman, MD, MMM</i>  |          | Gastroesophageal Reflux  | 57        |
| Current Context   | 1        | Infections in the Newborn Infant                                   | 58        |
| Strategies and Models for Quality Improvement (QI)  | 4        | Bacterial Infections   | 58        |
| Principles of Patient Safety (Incident Reporting, Just Culture, Disclosure, FMEA, RCA, Reliability, Checklists) | 7        | Fungal Sepsis  | 61        |
| <b>2. The Newborn Infant</b>  | <b>9</b> | Congenital Infections  | 62        |
| <i>Adam A. Rosenberg, MD</i>  |          | Perinatally Acquired Infections                                    | 65        |
| <i>Theresa Grover, MD</i>   |          | Hematologic Disorders in the Newborn Infant                        | 67        |
| The Neonatal History  | 9        | Bleeding Disorders   | 67        |
| Assessment of Growth & Gestational Age  | 9        | Anemia   | 68        |
| Examination at Birth  | 12       | Polycythemia   | 69        |
| Examination in the Nursery  | 13       | Renal Disorders in the Newborn Infant                              | 69        |
| Care of the Well Neonate  | 15       | Renal Failure  | 70        |
| Feeding the Well Neonate  | 16       | Urinary Tract Anomalies  | 70        |
| Early Discharge of the Newborn Infant   | 18       | Renal Vein Thrombosis  | 71        |
| Circumcision  | 18       | Neurologic Problems in the Newborn Infant                          | 71        |
| Hearing Screening   | 19       | Seizures   | 71        |
| Common Problems in the Term Newborn   | 19       | Hypotonia  | 72        |
| Neonatal Jaundice   | 19       | Intracranial Hemorrhage  | 72        |
| Hypoglycemia  | 27       | Metabolic Disorders in the Newborn Infant                          | 73        |
| Respiratory Distress in the term Newborn Infant   | 28       | Hyperglycemia  | 73        |
| Heart Murmurs   | 30       | Hypocalcemia   | 73        |
| Birth Trauma  | 31       | Inborn Errors of Metabolism  | 74        |
| Infants of Mothers Who Abuse Drugs  | 32       | Quality Assessment and Improvement in the Newborn Nursery and NICU | 74        |
| Multiple Births   | 34       | <b>3. Child Development &amp; Behavior</b>                         | <b>75</b> |
| Neonatal Intensive Care   | 35       | <i>Edward Goldson, MD</i>  |           |
| Perinatal Resuscitation   | 35       | <i>Ann Reynolds, MD</i>  |           |
| The Preterm Infant  | 40       | Normal Development   | 75        |
| The Late Preterm Infant   | 50       | The First 2 Years  | 75        |
| Cardiac Problems in the Newborn Infant  | 52       | Ages 2–4 Years   | 92        |
| Structural Heart Disease  | 52       | Early School Years: Ages 5–7 Years                                 | 92        |
| Persistent Pulmonary Hypertension   | 53       | Middle Childhood: Ages 7–11 Years                                  | 92        |
| Arrhythmias   | 53       | Behavioral & Developmental Variations                              | 93        |
| Gastrointestinal & Abdominal Surgical   |          | Normality & Temperament  | 93        |
| Conditions in the Newborn Infant  | 54       | Enuresis & Encopresis  | 94        |
| Esophageal Atresia & Tracheoesophageal Fistula  | 54       | Enuresis   | 94        |
| Intestinal Obstruction  | 54       | Encopresis   | 95        |
|   |          | Common Developmental Concerns                                      | 96        |
|   |          | Colic  | 96        |
|   |          | Feeding Disorders in Infants & Young Children                      | 97        |
|   |          | Sleep Disorders  | 99        |
|   |          | Temper Tantrums & Breath-Holding Spells                            | 101       |
|   |          | Well-Child Surveillance & Screening                                | 103       |
|   |          | Developmental Disorders  | 104       |

|  |     |
|--|-----|
| Attention-Deficit Hyperactivity Disorder                                   | 105 |
| Autism Spectrum Disorders  | 107 |
| Intellectual Disability  | 112 |
| Specific Forms of Intellectual Disability &<br>Associated Treatment Issues | 114 |

#### 4. Adolescence 117

|  |     |
|--|-----|
| <i>Amy E. Sass, MD, MPH</i>                            |     |
| <i>David W. Kaplan, MD, MPH</i>                        |     |
| Demography   | 117 |
| Mortality Data   | 117 |
| Morbidity Data   | 117 |
| Delivery of Health Services                            | 119 |
| Guidelines for Adolescent Preventive Services          | 119 |
| Relating to the Adolescent Patient                     | 119 |
| The Setting  | 119 |
| Confidentiality  | 120 |
| The Structure of the Visit                             | 120 |
| Growth & Development                                   | 125 |
| Puberty  | 125 |
| Physical Growth  | 126 |
| Sexual Maturation                                      | 127 |
| Psychosocial Development                               | 127 |
| Behavior & Psychological Health                        | 129 |
| Psychophysiological Symptoms & Conversion<br>Reactions | 129 |
| Depression   | 130 |
| Adolescent Suicide                                     | 131 |
| Substance Abuse  | 132 |
| Eating Disorders                                       | 132 |
| Overweight & Obesity                                   | 132 |
| School Avoidance                                       | 134 |
| School Failure   | 135 |
| Breast Disorders                                       | 135 |
| Breast Masses  | 136 |
| Nipple Discharge & Galactorrhea                        | 137 |
| Gynecomastia   | 138 |
| Gynecologic Disorders in Adolescence                   | 139 |
| Physiology of Menstruation                             | 139 |
| Pelvic Examination                                     | 140 |
| Menstrual Disorders                                    | 141 |
| Contraception  | 149 |
| Pregnancy  | 155 |

#### 5. Adolescent Substance Abuse 158

|  |     |
|--|-----|
| <i>Paritosh Kaul, MD</i>                     |     |
| Scope of the Problem                         | 158 |
| Morbidity Data                               | 163 |
| Predicting the Progression From Use to Abuse | 164 |
| Evaluation of Substance Abuse                | 165 |
| Treatment & Referral                         | 168 |
| Prevention                                   | 170 |

#### 6. Eating Disorders 172

|   |     |
|---|-----|
| <i>Eric J. Sigel, MD</i>                                    |     |
| Etiology  | 172 |
| Incidence   | 173 |
| Predisposing Factors & Clinical Profiles                    | 174 |
| Anorexia Nervosa  | 174 |
| Bulimia Nervosa   | 180 |
| Binge-Eating Disorder                                       | 182 |
| Eating Disorders Not Meeting<br>Criteria for Categorization | 183 |
| Avoidant/Restrictive Food Intake Disorder                   | 183 |
| Prognosis   | 184 |
| Resources for Practitioners and Families                    | 184 |

#### 7. Child & Adolescent Psychiatric Disorders & Psychosocial Aspects of Pediatrics 185

|   |     |
|---|-----|
| <i>Adam Burstein, DO</i>  |     |
| <i>Ayelet Talmi, PhD</i>  |     |
| <i>Brian Stafford, MD, MPH</i>  |     |
| <i>Kimberly Kelsay, MD</i>  |     |
| Models of Care Encompassing Mental<br>Health in the Primary Care Setting        | 186 |
| Early Identification & Prevention of<br>Developmental & Socioemotional Problems | 186 |
| Identification & Assessment During Health<br>Maintenance Visits                 | 187 |
| Consultation-Liaison Psychiatry   | 195 |
| The Chronically Ill Child   | 195 |
| The Terminally Ill Child  | 196 |
| Psychiatric Disorders of Childhood<br>& Adolescence                             | 199 |
| Pediatric Primary Care Behavioral Health Services                               | 200 |
| Anxiety Disorders   | 202 |
| Attention-Deficit Hyperactivity Disorder  | 210 |
| Mood Disorders  | 215 |
| Suicide in Children & Adolescents   | 226 |
| Conduct Disorders   | 228 |
| High-Risk Patients and Homicide   | 232 |
| Somatoform Disorders  | 233 |
| Adjustment Disorders  | 234 |
| Psychotic Disorders   | 235 |
| Other Psychiatric Conditions  | 238 |

#### 8. Child Abuse & Neglect 239

|                               |     |
|-------------------------------|-----|
| <i>Antonia Chiesa, MD</i>     |     |
| <i>Andrew P. Sirotnak, MD</i> |     |
| Prevention                    | 240 |
| Clinical Findings             | 240 |
| Differential Diagnosis        | 245 |
| Treatment                     | 246 |
| Prognosis                     | 246 |

**9. Ambulatory & Office Pediatrics 248**

|   |     |
|---|-----|
| <i>Meghan Treitz, MD</i>                        |     |
| <i>Maya Bunik, MD, MSPH</i>                     |     |
| <i>David Fox, MD</i>                            |     |
| Pediatric History                               | 248 |
| Pediatric Physical Examination                  | 249 |
| Health Supervision Visits                       | 251 |
| Developmental & Behavioral Assessment           | 251 |
| Growth Parameters                               | 254 |
| Blood Pressure                                  | 255 |
| Vision & Hearing Screening                      | 256 |
| Screening                                       | 257 |
| Anticipatory Guidance                           | 260 |
| Nutrition Counseling                            | 262 |
| Counseling About Television &<br>Other Media    | 262 |
| Immunizations                                   | 263 |
| Acute-Care Visits                               | 263 |
| Prenatal Visits                                 | 264 |
| Sports Physicals                                | 264 |
| Chronic Disease Management                      | 264 |
| Medical Home                                    | 265 |
| Mental & Behavioral Health                      | 265 |
| Consultations                                   | 266 |
| Telephone Management & Web-Based<br>Information | 266 |
| Advocacy & Community Pediatrics                 | 267 |
| Common General Pediatric Issues                 | 267 |
| Fever   | 267 |
| Growth Deficiency                               | 269 |

**10. Immunization 271**

|   |     |
|---|-----|
| <i>Matthew F. Daley, MD</i>                           |     |
| <i>Sean T. O'Leary, MD, MPH</i>                       |     |
| <i>Ann-Christine Nyquist, MD, MSPH</i>                |     |
| Standards for Pediatric Immunization Practices        | 272 |
| Routine Childhood & Adolescent Immunization           |     |
| Schedules   | 273 |
| Vaccine Safety  | 273 |
| Vaccination in Special Circumstances                  | 277 |
| Hepatitis B Vaccination                               | 278 |
| Rotavirus Vaccination                                 | 281 |
| Diphtheria-Tetanus-Acellular<br>Pertussis Vaccination | 282 |
| <i>Haemophilus Influenzae</i><br>Type B Vaccination   | 285 |
| Pneumococcal Vaccination                              | 286 |
| Poliomyelitis Vaccination                             | 288 |
| Influenza Vaccination                                 | 289 |
| Measles, Mumps, &<br>Rubella Vaccination              | 291 |
| Varicella Vaccination                                 | 293 |

|   |     |
|---|-----|
| Hepatitis A Vaccination   | 295 |
| Meningococcal Vaccination   | 296 |
| Tetanus-Reduced Diphtheria-Acellular<br>Pertussis Vaccination<br>(Adolescents & Adults) | 298 |
| Human Papillomavirus Vaccination  | 299 |
| Vaccinations for Special Situations   | 299 |
| Rabies Vaccination  | 299 |
| Typhoid Fever Vaccination   | 301 |
| Japanese Encephalitis Vaccination   | 301 |
| Tuberculosis Vaccination  | 302 |
| Yellow Fever Vaccination  | 303 |
| Passive Prophylaxis   | 303 |

**11. Normal Childhood Nutrition & Its Disorders 305**

|  |     |
|--|-----|
| <i>Matthew A. Haemer, MD MPH</i>       |     |
| <i>Laura E. Primak, RD, CNSD, CSP</i>  |     |
| <i>Nancy F. Krebs, MD, MS</i>          |     |
| Nutritional Requirements               | 305 |
| Nutrition & Growth                     | 305 |
| Energy                                 | 305 |
| Protein                                | 307 |
| Lipids                                 | 307 |
| Carbohydrates                          | 308 |
| Major Minerals                         | 309 |
| Trace Elements                         | 309 |
| Vitamins                               | 309 |
| Infant Feeding                         | 311 |
| Breast-Feeding                         | 311 |
| Special Dietary Products for Infants   | 320 |
| Nutrition for Children 2 Years & Older | 321 |
| Pediatric Undernutrition               | 321 |
| Pediatric Overweight & Obesity         | 323 |
| Nutrition Support                      | 326 |
| 1. Enteral                             | 326 |
| 2. Parenteral Nutrition                | 327 |
| Nutrient Requirements & Delivery       | 329 |

**12. Emergencies & Injuries 334**

|   |     |
|---|-----|
| <i>Maria J. Mandt, MD</i>                                     |     |
| <i>Joseph A. Grubenhoff, MD</i>                               |     |
| Assessment & Management of the Acutely<br>Ill Infant or Child | 334 |
| The ABCs of Resuscitation                                     | 334 |
| Management of Shock   | 338 |
| Summary of Resuscitating the Acutely Ill<br>Infant or Child   | 339 |
| Emergency Pediatric Drugs                                     | 340 |
| Approach to the Acutely Ill Infant or Child                   | 340 |
| Preparation for Emergency Management                          | 340 |
| Reception & Assessment  | 340 |

|  |     |   |     |
|--|-----|---|-----|
| Approach to the Pediatric Trauma Patient | 342 | Disk-Shaped “Button” Batteries  | 373 |
| Mechanism of Injury                      | 342 | Ethylene Glycol & Methanol  | 374 |
| Initial Assessment & Management          | 342 | γ-Hydroxybutyrate, γ-Butyrolactone,<br>& Butanediol   | 374 |
| Primary Survey                           | 343 | Hydrocarbons (Benzene, Charcoal Lighter<br>Fluid, Gasoline, Kerosene, Petroleum<br>Distillates, Turpentine) | 374 |
| Secondary Survey                         | 345 | Ibuprofen   | 375 |
| Head Injury                              | 347 | Insect Stings (Bee, Wasp, & Hornet)   | 375 |
| Burns                                    | 349 | Insecticides  | 375 |
| Thermal Burns                            | 349 | Iron  | 376 |
| Electrical Burns                         | 351 | Lead  | 377 |
| Disorders Due to Extremes of Environment | 351 | Magnets   | 378 |
| Heat-Related Illnesses & Heat Stroke     | 351 | Mushrooms   | 378 |
| Hypothermia                              | 352 | Nitrites, Nitrates, Aniline, Pentachlorophenol,<br>& Dinitrophenol  | 378 |
| Submersion Injuries                      | 353 | Opioids & Opiates   | 379 |
| Animal & Human Bites                     | 354 | Oral Hypoglycemics (Sulfonylureas, Metformin)   | 380 |
| Dog Bites                                | 354 | Antipsychotics (Typical & Atypical)   | 380 |
| Cat Bites                                | 355 | Plants  | 381 |
| Human Bites                              | 355 | Psychotropic Drugs  | 381 |
| Procedural Sedation & Analgesia          | 355 | Salicylates   | 382 |

### 13. Poisoning 357

|   |     |
|---|-----|
| <i>George Sam Wang, MD</i>  |     |
| <i>Barry H. Rumack, MD</i>  |     |
| <i>Richard C. Dart, MD, PhD</i>   |     |
| Pharmacologic Principles of Toxicology  | 357 |
| Preventing Childhood Poisonings   | 358 |
| General Treatment of Poisoning  | 358 |
| Initial Telephone Contact   | 358 |
| Initial Emergency Department Contact  | 361 |
| Definitive Therapy of Poisoning   | 361 |
| Management of Specific Common Poisonings  | 363 |
| Acetaminophen (Paracetamol)   | 363 |
| Alcohol, Ethyl (Ethanol)  | 363 |
| Amphetamines & Related Drugs<br>(Methamphetamine, MDMA)                                   | 365 |
| Anesthetics, Local  | 366 |
| Antihistamines & Cough & Cold Preparations  | 367 |
| Arsenic   | 367 |
| Barbiturates & Benzodiazepines  | 368 |
| Belladonna Alkaloids (Atropine,<br>Jimsonweed, Potato Leaves, Scopolamine,<br>Stramonium) | 368 |
| β-Blockers & Calcium Channel Blockers   | 369 |
| Carbon Monoxide   | 369 |
| Caustics  | 369 |
| Central Alpha-2 Adrenergic Agonist  | 370 |
| Cocaine   | 371 |
| Contraceptive Pills   | 371 |
| Cosmetics & Related Products  | 371 |
| Cyclic Antidepressants  | 372 |
| Digitalis & Other Cardiac Glycosides  | 372 |
| Diphenoxylate with Atropine (Lomotil) &<br>Loperamide (Imodium)                           | 373 |
| Disinfectants & Deodorizers   | 373 |

|  |     |
|--|-----|
| Plants   | 381 |
| Psychotropic Drugs   | 381 |
| Scorpion Stings  | 383 |
| Serotonin Reuptake Inhibitors                                      | 383 |
| Snakebite  | 384 |
| Soaps & Detergents   | 385 |
| Spider Bites   | 385 |
| Thyroid Preparations (Thyroid Desiccated,<br>Sodium Levothyroxine) | 386 |
| Vitamins   | 386 |
| Warfarin (Coumadin) and Other Oral<br>Anticoagulants               | 386 |

### 14. Critical Care 387

|   |     |
|---|-----|
| <i>Todd C. Carpenter, MD,</i>                                 |     |
| <i>Angela S. Czaja, MD, MSc,</i>                              |     |
| <i>Jennifer Exo, DO, Eva N. Grayck, MD,</i>                   |     |
| <i>Cameron F. Gunville, DO, Carleen Zebuhr, MD</i>            |     |
| Introduction  | 387 |
| Respiratory Critical Care                                     | 387 |
| Acute Respiratory Failure                                     | 387 |
| Conventional Mechanical Ventilation                           | 391 |
| Major Respiratory Diseases in the Pediatric ICU               | 395 |
| Acute Respiratory Distress Syndrome                           | 395 |
| Status Asthmaticus  | 399 |
| Cardiovascular Critical Care                                  | 402 |
| Shock   | 402 |
| Sepsis  | 405 |
| Neurocritical Care  | 409 |
| Traumatic Brain Injury  | 409 |
| Hypoxic-Ischemic Encephalopathy                               | 413 |
| Additional Therapeutic Considerations<br>in the Pediatric ICU | 414 |

|  |     |
|--|-----|
| Acute Kidney Injury and Renal Replacement Therapy                    | 414 |
| Fluid Management and Nutritional Support of the Critically Ill Child | 415 |
| Sedation & Analgesia in the Pediatric ICU                            | 418 |
| End-of-Life Care and Death in the PICU                               | 422 |
| Quality Improvement Initiatives in the PICU                          | 424 |

## 15. Skin 426

|   |     |
|---|-----|
| <i>Joseph G. Morelli, MD</i>                                  |     |
| <i>Lori D. Prok, MD</i>                                       |     |
| General Principles  | 426 |
| Diagnosis of Skin Disorders                                   | 426 |
| Treatment of Skin Disorders                                   | 426 |
| Disorders of the Skin in Newborns                             | 428 |
| Transient Diseases in Newborns                                | 428 |
| Pigment Cell Birthmarks, Nevi, & Melanoma                     | 429 |
| Melanocytic Nevi  | 430 |
| Vascular Birthmarks   | 430 |
| Epidermal Birthmarks  | 431 |
| Connective Tissue Birthmarks (Juvenile Elastoma, Collagenoma) | 432 |
| Hereditary Skin Disorders                                     | 432 |
| Common Skin Diseases in Infants, Children, & Adolescents      | 432 |
| Acne  | 432 |
| Bacterial Infections of the Skin                              | 435 |
| Fungal Infections of the Skin                                 | 436 |
| Viral Infections of the Skin                                  | 437 |
| Virus-Induced Tumors  | 438 |
| Insect Infestations   | 438 |
| Dermatitis (Eczema)   | 439 |
| Common Skin Tumors  | 442 |
| Papulosquamous Eruptions                                      | 443 |
| Hair Loss (Alopecia)  | 444 |
| Reactive Erythemas  | 445 |
| Miscellaneous Skin Disorders Seen in Pediatric Practice       | 445 |

## 16. Eye 447

|                                     |     |
|-------------------------------------|-----|
| <i>Rebecca Sands Braverman, MD</i>  |     |
| Common Nonspecific Signs & Symptoms | 447 |
| Red Eye                             | 447 |
| Tearing                             | 447 |
| Discharge                           | 447 |
| Pain & Foreign Body Sensation       | 447 |
| Photophobia                         | 447 |
| Leukocoria                          | 448 |
| Refractive Errors                   | 448 |
| Myopia (Nearsightedness)            | 449 |
| Hyperopia (Farsightedness)          | 449 |
| Astigmatism                         | 449 |

|  |     |
|--|-----|
| Ophthalmic Examination                                   | 449 |
| History  | 449 |
| Visual Acuity  | 449 |
| External Examination                                     | 450 |
| Pupils   | 451 |
| Alignment & Motility Evaluation                          | 451 |
| Ophthalmoscopic Examination                              | 453 |
| Ocular Trauma  | 453 |
| Ocular Foreign Bodies                                    | 453 |
| Corneal Abrasion   | 454 |
| Intraocular Foreign Bodies & Perforating Ocular Injuries | 455 |
| Blunt Orbital Trauma                                     | 455 |
| Lacerations  | 456 |
| Burns  | 457 |
| Hyphema  | 457 |
| Abusive Head Trauma & Nonaccidental Trauma               | 458 |
| Prevention of Ocular Injuries                            | 459 |
| Disorders of the Ocular Structures                       | 459 |
| Diseases of the Eyelids                                  | 459 |
| Viral Eyelid Disease                                     | 460 |
| Miscellaneous Eyelid Infections                          | 461 |
| Eyelid Ptosis  | 461 |
| Horner Syndrome  | 462 |
| Eyelid Tics  | 463 |
| Disorders of the Nasolacrimal System                     | 463 |
| Nasolacrimal Duct Obstruction                            | 463 |
| Congenital Dacryocystocele                               | 463 |
| Dacryocystitis   | 464 |
| Diseases of the Conjunctiva                              | 465 |
| Ophthalmia Neonatorum                                    | 465 |
| Bacterial Conjunctivitis                                 | 466 |
| Viral Conjunctivitis                                     | 466 |
| Allergic Conjunctivitis                                  | 467 |
| Mucocutaneous Diseases                                   | 467 |
| Disorders of the Iris                                    | 469 |
| Iris Coloboma  | 469 |
| Aniridia   | 469 |
| Albinism   | 470 |
| Miscellaneous Iris Conditions                            | 470 |
| Glaucoma   | 470 |
| Uveitis  | 471 |
| Anterior Uveitis/Iridocyclitis/Iritis                    | 471 |
| Posterior Uveitis  | 472 |
| Intermediate Uveitis                                     | 473 |
| Ocular Manifestations of AIDS                            | 473 |
| Disorders of the Cornea                                  | 474 |
| Cloudy Cornea  | 474 |
| Viral Keratitis  | 474 |
| Corneal Ulcers   | 475 |
| Disorders of the Lens                                    | 475 |
| Cataracts  | 476 |
| Dislocated Lenses/Ectopia Lentis                         | 476 |



|   |     |   |     |
|---|-----|---|-----|
| Disorders of the Retina                               | 477 | Epistaxis   | 521 |
| Retinal Hemorrhages in the Newborn                    | 477 | Nasal Infection   | 521 |
| Retinopathy of Prematurity                            | 477 | Nasal Trauma  | 521 |
| Retinoblastoma  | 478 | Foreign Bodies in the Nose                              | 522 |
| Retinal Detachment                                    | 479 | The Throat & Oral Cavity                                | 522 |
| Diabetic Retinopathy                                  | 479 | Acute Stomatitis  | 522 |
| Diseases of the Optic Nerve                           | 480 | Pharyngitis   | 523 |
| Optic Neuropathy                                      | 480 | Peritonsillar Cellulitis or Abscess (Quinsy)            | 526 |
| Optic Nerve Hypoplasia                                | 480 | Retropharyngeal Abscess                                 | 526 |
| Papilledema   | 481 | Ludwig Angina   | 527 |
| Optic Neuritis  | 482 | Acute Cervical Adenitis                                 | 527 |
| Optic Atrophy   | 482 | Snoring, Mouth Breathing, & Upper Airway<br>Obstruction | 528 |
| Periorbital & Orbital Cellulitis                      | 483 | Tonsillectomy & Adenoidectomy                           | 530 |
| Craniofacial Anomalies                                | 483 | Disorders of the Lips                                   | 531 |
| Orbital Tumors  | 484 | Disorders of the Tongue                                 | 531 |
| Nystagmus   | 485 | Halitosis   | 532 |
| Amblyopia   | 485 | Salivary Gland Disorders                                | 532 |
| Strabismus  | 486 | Congenital Oral Malformations                           | 532 |
| Unexplained Decreased Vision in Infants<br>& Children | 488 |   |     |
| Learning Disabilities & Dyslexia                      | 488 |   |     |

## 17. Oral Medicine & Dentistry 490

|  |     |
|--|-----|
| <i>Ulrich Klein, DMD, DDS, MS</i>        |     |
| Issues in Pediatric Oral Health          | 490 |
| Dental Caries                            | 492 |
| Oral Examination of the Newborn & Infant | 495 |
| Eruption of the Teeth                    | 497 |
| Periodontal Disease                      | 498 |
| Dental Emergencies                       | 499 |
| Antibiotics in Pediatric Dentistry       | 500 |
| Special Patient Populations              | 500 |
| Orthodontic Referral                     | 501 |

## 18. Ear, Nose, & Throat 502

|   |     |
|---|-----|
| <i>Norman R. Friedman, MD</i>                   |     |
| <i>Melissa A. Scholes, MD</i>                   |     |
| <i>Patricia J. Yoon, MD</i>                     |     |
| The Ear   | 502 |
| Infections of the Ear                           | 502 |
| Acute Trauma to the Middle Ear                  | 512 |
| Cerumen Impaction and Ear Canal<br>Foreign Body | 512 |
| Auricular Hematoma                              | 512 |
| Congenital Ear Malformations                    | 513 |
| Identification & Management of<br>Hearing Loss  | 513 |
| The Nose & Paranasal Sinuses                    | 515 |
| Acute Viral Rhinitis                            | 515 |
| Rhinosinusitis                                  | 518 |
| Choanal Atresia                                 | 520 |
| Recurrent Rhinitis                              | 520 |

## 19. Respiratory Tract & Mediastinum 534

|  |     |
|--|-----|
| <i>Monica J. Federico, MD, Christopher D. Baker, MD</i>              |     |
| <i>Vivek Balasubramaniam, MD, Emily M. Deboer, MD</i>                |     |
| <i>Robin R. Deterding, MD, Ann Halbower, MD</i>                      |     |
| <i>Oren Kupfer, MD, Stacey L. Martiniano, MD</i>                     |     |
| <i>Scott D. Sagel, MD, Paul Stillwell, MD</i>                        |     |
| <i>Edith T. Zemanick, MD</i>   |     |
| Respiratory Tract  | 534 |
| Growth & Development   | 534 |
| Diagnostic AIDS  | 535 |
| Physical Examination of the Respiratory Tract                        | 535 |
| Pulmonary Function Tests   | 536 |
| Assessment of Oxygenation & Ventilation                              | 537 |
| Diagnosis of Respiratory Tract Infections                            | 539 |
| Imaging of the Respiratory Tract                                     | 540 |
| Laryngoscopy & Bronchoscopy  | 540 |
| General Therapy of Pediatric Lung Diseases                           | 541 |
| Oxygen Therapy   | 541 |
| Inhalation of Medications  | 541 |
| Airway Clearance Therapy   | 542 |
| Avoidance of Environmental Hazards                                   | 542 |
| Disorders of the Conducting Airways                                  | 543 |
| Laryngomalacia & Congenital Disorders of the<br>Extrathoracic Airway | 544 |
| Laryngomalacia   | 544 |
| Other Causes of Congenital Extrathoracic<br>Obstruction              | 544 |
| Acquired Disorders of the Extrathoracic Airway                       | 544 |
| Foreign Body Aspiration in the Extrathoracic<br>Airway               | 545 |
| Croup Syndromes  | 545 |
| Vocal Cord Paralysis   | 548 |
| Subglottic Stenosis  | 548 |

|  |     |
|--|-----|
| Congenital Causes of Intrathoracic Airway                                  |     |
| Obstruction  | 548 |
| Malacia of Airways   | 548 |
| Vascular Rings and Slings  | 549 |
| Bronchogenic Cysts   | 549 |
| Acquired Causes of Intrathoracic Airway                                    |     |
| Obstruction  | 550 |
| Foreign Body Aspiration in the Intrathoracic Airway                        | 550 |
| Disorders of Mucociliary Clearance   | 551 |
| Cystic Fibrosis  | 551 |
| Primary Ciliary Dyskinesia   | 552 |
| Bronchiolitis Obliterans   | 553 |
| Bronchiectasis   | 554 |
| Congenital Malformations of the Lung Parenchyma                            | 555 |
| Pulmonary Agenesis & Hypoplasia  | 555 |
| Pulmonary Sequestration  | 556 |
| Congenital Lobar Emphysema   | 557 |
| Congenital Pulmonary Airway Malformation (Cystic Adenomatoid Malformation) | 557 |
| Acquired Abnormalities of the Lung Parenchyma                              | 559 |
| Bronchopulmonary Dysplasia   | 559 |
| Community-Acquired Bacterial Pneumonia                                     | 561 |
| Parapneumonic Effusion & Empyema   | 562 |
| Atypical Pneumonias  | 563 |
| Viral Pneumonia  | 563 |
| Bronchiolitis  | 564 |
| Mycoplasma Pneumonia   | 566 |
| Tuberculosis   | 566 |
| Aspiration Pneumonia   | 568 |
| Pneumonia in the Immunocompromised Host                                    | 569 |
| Lung Abscess   | 571 |
| Children's Interstitial Lung Disease Syndrome                              | 572 |
| Hypersensitivity Pneumonitis   | 573 |
| Diseases of the Pulmonary Circulation                                      | 574 |
| Pulmonary Hemorrhage   | 574 |
| Pulmonary Embolism   | 576 |
| Pulmonary Edema  | 576 |
| Congenital Pulmonary Lymphangiectasia                                      | 577 |
| Disorders of the Chest Wall & Diaphragm                                    | 578 |
| Scoliosis  | 578 |
| Pectus Carinatum   | 578 |
| Pectus Excavatum   | 578 |
| Neuromuscular Disorders  | 578 |
| Eventration of the Diaphragm   | 579 |
| Disorders of the Pleura & Pleural Cavity                                   | 579 |
| Hemothorax   | 580 |
| Chylothorax  | 580 |
| Pneumothorax & Related Air Leak Syndromes                                  | 580 |
| Mediastinum  | 581 |
| Mediastinal Masses   | 581 |
| Sleep-Disordered Breathing   | 582 |
| Obstructive & Central Sleep Apnea  | 582 |
| Apparent Life-Threatening Events   | 583 |
| Sudden Infant Death Syndrome   | 586 |

## 20. Cardiovascular Diseases

588

|   |     |
|---|-----|
| <i>Jeffrey R. Darst, MD</i>                             |     |
| <i>Kathryn K. Collins, MD</i>                           |     |
| <i>Shelley D. Miyamoto, MD</i>                          |     |
| Diagnostic Evaluation                                   | 588 |
| History   | 588 |
| Physical Examination                                    | 588 |
| Electrocardiography                                     | 591 |
| Chest Radiograph  | 593 |
| Echocardiography  | 594 |
| Nuclear Cardiology                                      | 595 |
| Magnetic Resonance Imaging                              | 595 |
| Cardiopulmonary Stress Testing                          | 595 |
| Arterial Blood Gases                                    | 595 |
| Cardiac Catheterization & Angiocardiology               | 596 |
| Perinatal & Neonatal Circulation                        | 598 |
| Heart Failure   | 598 |
| Genetic Basis of Congenital Heart Disease               | 601 |
| Acyanotic Congenital Heart Disease                      | 601 |
| Defects in Septation                                    | 601 |
| Patent (Persistent) Ductus Arteriosus                   | 605 |
| Right-Sided Obstructive Lesions                         | 607 |
| Left-Sided Lesions                                      | 610 |
| Diseases of the Aorta                                   | 614 |
| Coronary Artery Abnormalities                           | 615 |
| Cyanotic Congenital Heart Disease                       | 616 |
| Tetralogy of Fallot                                     | 616 |
| Pulmonary Atresia with Ventricular Septal Defect        | 618 |
| Pulmonary Atresia with Intact Ventricular Septum        | 618 |
| Tricuspid Atresia                                       | 619 |
| Hypoplastic Left Heart Syndrome                         | 620 |
| Transposition of the Great Arteries                     | 621 |
| Total Anomalous Pulmonary Venous Return                 | 623 |
| Truncus Arteriosus                                      | 625 |
| Quality Improvement in Congenital Heart Disease         | 626 |
| Acquired Heart Disease                                  | 626 |
| Rheumatic Fever   | 626 |
| Kawasaki Disease  | 628 |
| Infective Endocarditis                                  | 629 |
| Pericarditis  | 631 |
| Cardiomyopathy  | 632 |
| Myocarditis   | 634 |
| Preventive Cardiology                                   | 635 |
| Hypertension  | 635 |
| Atherosclerosis & Dyslipidemias                         | 636 |
| Chest Pain  | 636 |
| Cardiac Transplantation                                 | 637 |
| Quality Improvement for Pediatric Heart Transplantation | 639 |
| Primary Pulmonary Hypertension                          | 639 |
| Disorders of Rate & Rhythm                              | 640 |

|  |            |  |            |
|--|------------|--|------------|
| Disorders of the Sinus Node                                | 640        | Gastrointestinal Tumors & Malignancies   | 676        |
| Sinus Arrhythmia   | 640        | Juvenile Polyps  | 676        |
| Sinus Bradycardia  | 641        | Cancers of the Esophagus,<br>Small Bowel, & Colon                                | 676        |
| Sinus Tachycardia  | 641        | Mesenteric Cysts   | 677        |
| Sinus Node Dysfunction                                     | 641        | Intestinal Hemangiomas and Vascular<br>Malformations                             | 677        |
| Premature Beats  | 641        | Major Gastrointestinal Symptoms & Signs  | 678        |
| Supraventricular Tachycardia                               | 641        | Acute Diarrhea   | 678        |
| Ventricular Tachycardia                                    | 646        | Chronic Diarrhea   | 679        |
| Long QT Syndrome   | 647        | Gastrointestinal Bleeding  | 681        |
| Sudden Death   | 647        | Vomiting   | 684        |
| Disorders of Atrioventricular Conduction                   | 648        | Recurrent Abdominal Pain   | 685        |
| Syncope (Fainting)   | 650        | Acute Abdomen  | 686        |
|  |            | Malabsorption Syndromes  | 687        |
|  |            | Inflammatory Bowel Disease   | 691        |
| <b>21. Gastrointestinal Tract</b>                          | <b>651</b> |  |            |
| <i>Edward Hoffenberg, MD</i>                               |            | <b>22. Liver &amp; Pancreas</b>  | <b>695</b> |
| <i>David Brumbaugh, MD</i>                                 |            | <i>Ronald J. Sokol, MD</i>   |            |
| <i>Glenn T. Furuta, MD</i>                                 |            | <i>Michael R. Narkewicz, MD</i>  |            |
| <i>Gregg Kobak, MD</i>                                     |            | <i>Shikha S. Sundaram, MD MSCI</i>   |            |
| <i>Edwin Liu, MD</i>                                       |            | <i>Cara L. Mack, MD</i>  |            |
| <i>Jason Soden, MD</i>                                     |            | Liver Disorders  | 695        |
| <i>Robert Kramer, MD</i>                                   |            | Prolonged Neonatal<br>Cholestatic Jaundice                                       | 695        |
| Disorders of the Esophagus                                 | 651        | Intrahepatic Cholestasis   | 695        |
| Gastroesophageal Reflux & GERD                             | 651        | Extrahepatic Neonatal Cholestasis  | 703        |
| Eosinophilic Esophagitis                                   | 653        | Other Neonatal<br>Hyperbilirubinemic Conditions<br>(Noncholestatic Nonhemolytic) | 706        |
| Achalasia of the Esophagus                                 | 654        | Hepatitis A  | 708        |
| Caustic Burns of the Esophagus                             | 655        | Hepatitis B  | 710        |
| Foreign Bodies in the Alimentary Tract                     | 656        | Hepatitis C  | 712        |
| Disorders of the Stomach & Duodenum                        | 658        | Hepatitis D (Delta Agent)  | 713        |
| Hiatal Hernia  | 658        | Hepatitis E  | 714        |
| Pyloric Stenosis   | 658        | Other Hepatitis Viruses  | 714        |
| Gastric & Duodenal Ulcer                                   | 659        | Acute Liver Failure  | 714        |
| Congenital Diaphragmatic Hernia                            | 661        | Autoimmune Hepatitis   | 716        |
| Congenital Duodenal Obstruction                            | 661        | Nonalcoholic Fatty Liver Disease   | 717        |
| Disorders of the Small Intestine                           | 662        | $\alpha_1$ -Antitrypsin Deficiency Liver Disease                                 | 719        |
| Intestinal Atresia & Stenosis                              | 662        | Wilson Disease<br>(Hepatolenticular Degeneration)                                | 720        |
| Intestinal Malrotation                                     | 663        | Drug-Induced Liver Disease   | 721        |
| Short Bowel Syndrome                                       | 664        | Cirrhosis  | 722        |
| Intussusception  | 665        | Portal Hypertension  | 723        |
| Inguinal Hernia  | 666        | Biliary Tract Disease  | 726        |
| Umbilical Hernia   | 667        | Pyogenic & Amebic Liver Abscess  | 730        |
| Patent Omphalomesenteric Duct                              | 667        | Liver Tumors   | 732        |
| Meckel Diverticulum  | 667        | Liver Transplantation  | 733        |
| Acute Appendicitis   | 668        | Pancreatic Disorders Acute Pancreatitis  | 734        |
| Duplications of the Gastrointestinal Tract                 | 669        | Chronic Pancreatitis   | 735        |
| Disorders of the Colon                                     | 669        | Gastrointestinal & Hepatobiliary<br>Manifestations of Cystic Fibrosis            | 736        |
| Congenital Aganglionic Megacolon<br>(Hirschsprung Disease) | 669        |  |            |
| Constipation   | 670        |  |            |
| Anal Fissure   | 672        |  |            |
| Congenital Anorectal Anomalies                             | 672        |  |            |
| <i>Clostridium difficile</i> Infection in Children         | 673        |  |            |
| Disorders of the Peritoneal Cavity                         | 674        |  |            |
| Peritonitis  | 674        |  |            |
| Chylous Ascites  | 675        |  |            |

|  |     |
|--|-----|
| Syndromes with Pancreatic Exocrine Insufficiency | 740 |
| Isolated Exocrine Pancreatic Enzyme Defect       | 740 |
| Pancreatic Tumors                                | 740 |

### 23. Fluid, Electrolyte, & Acid-Base Disorders & Therapy 742

*Douglas M. Ford, MD*

|   |     |
|---|-----|
| Regulation of Body Fluids, Electrolytes, & Tonicity | 742 |
| Acid-Base Balance                                   | 744 |
| Fluid & Electrolyte Management                      | 745 |
| Dehydration   | 746 |
| Hyponatremia  | 748 |
| Hypernatremia                                       | 748 |
| Potassium Disorders                                 | 749 |
| Acid-Base Disturbances                              | 750 |
| Metabolic Acidosis                                  | 750 |
| Metabolic Alkalosis                                 | 751 |
| Respiratory Acidosis                                | 751 |
| Respiratory Alkalosis                               | 751 |

### 24. Kidney & Urinary Tract 752

*Gary M. Lum, MD*

|   |     |
|---|-----|
| Evaluation of the Kidney & Urinary Tract                            | 752 |
| History   | 752 |
| Physical Examination  | 752 |
| Laboratory Evaluation of Renal Function                             | 752 |
| Laboratory Evaluation of Immunologic Function                       | 754 |
| Radiographic Evaluation   | 755 |
| Renal Biopsy  | 756 |
| Congenital Anomalies of the Urinary Tract                           | 756 |
| Renal Parenchymal Anomalies   | 756 |
| Distal Urinary Tract Anomalies                                      | 757 |
| Hematuria & Glomerular Disease                                      | 757 |
| Microhematuria  | 757 |
| Glomerulonephritis  | 757 |
| Acute Interstitial Nephritis  | 760 |
| Proteinuria & Renal Disease   | 760 |
| Congenital Nephrosis  | 760 |
| Idiopathic Nephrotic Syndrome of Childhood (Minimal Change Disease) | 760 |
| Focal Glomerular Sclerosis  | 761 |
| Mesangial Nephropathy (Mesangial Glomerulonephritis)                | 761 |
| Membranous Nephropathy (Membranous Glomerulonephritis)              | 761 |
| Diseases of the Renal Vessels                                       | 761 |
| Renal Vein Thrombosis   | 761 |
| Renal Arterial Disease  | 762 |
| Hemolytic-Uremic Syndrome   | 762 |

|  |     |
|--|-----|
| Renal Failure  | 763 |
| Acute Renal Failure  | 763 |
| Chronic Renal Failure  | 765 |
| Hypertension   | 767 |
| Inherited or Developmental Defects of the Kidneys                              | 769 |
| Disorders of the Renal Tubules   | 769 |
| Oculocerebrorenal Syndrome (Lowe Syndrome)                                     | 771 |
| Hypokalemic Alkalosis (Bartter Syndrome, Gitelman Syndrome, & Liddle Syndrome) | 771 |
| Cystinosis   | 772 |
| Nephrogenic Diabetes Insipidus   | 772 |
| Nephrolithiasis  | 772 |
| Urinary Tract Infections   | 773 |

### 25. Neurologic & Muscular Disorders 776

*Sita Kedia, MD, Kelly Knupp, MD*

*Teri Schreiner, MD, MPH, Michele L. Yang, MD*

*Paul M. Levisohn, MD, Paul G. Moe, MD*

|  |     |
|--|-----|
| Neurological Assessment & Neurodiagnostics                           | 776 |
| History & Examination  | 776 |
| Diagnostic Testing   | 776 |
| Pediatric Neuroradiologic Procedures                                 | 778 |
| Disorders Affecting the Nervous System in Infants & Children         | 782 |
| Altered States of Consciousness                                      | 782 |
| Seizure Disorders (Epilepsies)                                       | 786 |
| Sleep Disorders  | 800 |
| Headaches  | 801 |
| Pseudotumor Cerebri (Idiopathic Intracranial Hypertension)           | 804 |
| Cerebrovascular Disease  | 806 |
| Congenital Malformations of the Nervous System                       | 809 |
| Abnormal Head Size   | 812 |
| Neurocutaneous Dysplasias  | 814 |
| Central Nervous System Degenerative Disorders of Infancy & Childhood | 818 |
| Ataxias of Childhood   | 824 |
| Acute Ataxias of Childhood   | 824 |
| Congenital Causes of Chronic & Episodic Ataxias                      | 827 |
| Intermittent/Episodic Ataxias  | 827 |
| Progressive Ataxias  | 828 |
| Extrapyramidal Disorders   | 829 |
| Cerebral Palsy   | 833 |
| Infections & Inflammatory Disorders of the Central Nervous System    | 835 |
| Bacterial Meningitis   | 836 |
| Brain Abscess  | 837 |
| Viral Infections   | 838 |

|  |            |   |            |
|--|------------|---|------------|
| Encephalopathy of Human                        |            |   |            |
| Immunodeficiency Virus Infection               | 838        | Neurologic Disorders Involving the          |            |
| Other Infections                               | 838        | Musculoskeletal System                      | 879        |
| Noninfectious Inflammatory Disorders           |            | Orthopedic Aspects of Cerebral Palsy        | 879        |
| of the Central Nervous System                  | 838        | Orthopedic Aspects of Myelodysplasia        | 880        |
| Other Parainfectious Encephalopathies          | 839        | Neoplasia of the Musculoskeletal System     | 880        |
| Multiple Sclerosis                             | 839        | Osteochondroma                              | 880        |
| Syndromes Presenting as Acute                  |            | Osteoid Osteoma                             | 880        |
| Flaccid Weakness                               | 841        | Enchondroma                                 | 881        |
| Disorders of Childhood Affecting Muscles       | 844        | Chondroblastoma                             | 881        |
| Benign Acute Childhood Myositis                | 853        | Nonossifying Fibroma                        | 881        |
| Myasthenic Syndromes                           | 853        | Osteosarcoma                                | 881        |
| Peripheral Nerve Palsies                       | 855        | Ewing Sarcoma                               | 881        |
| Chronic Polyneuropathy                         | 857        | Miscellaneous Diseases of Bone and Joint    | 882        |
| Miscellaneous Neuromuscular Disorders          | 858        | Fibrous Dysplasia                           | 882        |
| Floppy Infant Syndrome                         | 858        | Unicameral Bone Cyst                        | 882        |
| Web Resources                                  | 861        | Aneurysmal Bone Cyst                        | 882        |
|  |            | Infantile Cortical Hyperostosis             |            |
|  |            | (Caffey Syndrome)                           | 882        |
|  |            | Ganglion                                    | 883        |
|  |            | Baker Cyst                                  | 883        |
|  |            | National QI/QA Initiatives in Orthopedics   | 883        |
| <b>26. Orthopedics</b>                         | <b>862</b> |   |            |
| <i>Mark A. Erickson, MD, MMM</i>               |            | <b>27. Sports Medicine</b>                  | <b>884</b> |
| <i>Brendan Caprio, BS</i>                      |            | <i>Rachel A. Coel, MD, PhD, FAAP, CAQSM</i> |            |
| Disturbances of Prenatal Origin                | 862        | <i>Quynh B. Hoang, MD, FAAP, CAQSM</i>      |            |
| Congenital Amputations & Limb Deficiencies     | 862        | <i>Armando Vidal, MD</i>                    |            |
| Deformities of the Extremities                 | 863        | Basic Principles                            | 884        |
| Generalized Disorders of Skeletal or           |            | Fitness & Conditioning                      | 885        |
| Mesodermal Tissues                             | 865        | Sports Nutrition                            | 885        |
| Growth Disturbances of the Musculoskeletal     |            | Preparticipation Physical Evaluation        | 885        |
| System   | 867        | Rehabilitation of Sports Injuries           | 898        |
| Scoliosis                                      | 867        | Common Sports Medicine Issues & Injuries    | 899        |
| Slipped Capital Femoral Epiphysis              | 868        | Infectious Diseases                         | 899        |
| Genu Varum & Genu Valgum                       | 869        | Head & Neck Injuries                        | 900        |
| Tibial Torsion                                 | 869        | Spine Injuries                              | 902        |
| Femoral Anteversion                            | 869        | Shoulder Injuries                           | 904        |
| Common Foot Problems                           | 870        | Elbow Injuries                              | 906        |
| Degenerative Problems (Arthritis, Bursitis,    |            | Hand & Wrist Injuries                       | 908        |
| & Tenosynovitis)                               | 871        | Hip Injuries                                | 909        |
| Trauma   | 871        | Knee Injuries                               | 912        |
| Soft Tissue Trauma (Sprains, Strains,          |            | Foot & Ankle Injuries                       | 915        |
| & Contusions)                                  | 871        | Prevention                                  | 917        |
| Traumatic Subluxations & Dislocations          | 872        |   |            |
| Fractures                                      | 873        | <b>28. Rehabilitation Medicine</b>          | <b>918</b> |
| Infections of the Bones & Joints               | 874        | <i>Pamela E. Wilson, MD</i>                 |            |
| Osteomyelitis                                  | 874        | <i>Gerald H. Clayton, PhD</i>               |            |
| Tuberculous Arthritis                          | 877        | Pediatric Brain Injury                      | 918        |
| Diskitis                                       | 877        | Spinal Cord Injury                          | 921        |
| Transient (Toxic) Synovitis & Septic Arthritis |            | Brachial Plexus Lesions                     | 923        |
| of the Hip                                     | 877        | Common Rehabilitation Problems              | 924        |
| Vascular Lesions & Avascular Necrosis          |            | Quality Assurance/Improvement Initiatives   |            |
| (Osteochondroses)                              | 878        | in Rehabilitation Medicine                  | 926        |
| Avascular Necrosis of the Proximal Femur       |            |   |            |
| (Legg-Calvé-Perthes Disease)                   | 878        |   |            |
| Osteochondritis Dissecans                      | 879        |   |            |

**29. Rheumatic Diseases 927***Jennifer B. Soep, MD*

|                                |     |
|--------------------------------|-----|
| Juvenile Idiopathic Arthritis  | 927 |
| Systemic Lupus Erythematosus   | 930 |
| Dermatomyositis                | 932 |
| Vasculitis                     | 933 |
| Raynaud Phenomenon             | 934 |
| Noninflammatory Pain Syndromes | 934 |

**30. Hematologic Disorders 936***Daniel R. Ambruso, MD**Rachelle Nuss, MD**Michael Wang, MD*

|   |     |
|---|-----|
| Normal Hematologic Values   | 936 |
| Bone Marrow Failure   | 936 |
| Constitutional Aplastic Anemia<br>(Fanconi Anemia)                | 936 |
| Acquired Aplastic Anemia  | 937 |
| Anemias   | 938 |
| Approach to the Child with Anemia                                 | 938 |
| Pure Red Cell Aplasia   | 940 |
| Nutritional Anemias   | 942 |
| Anemia of Chronic Disorders                                       | 944 |
| Congenital Hemolytic Anemias: Red Cell<br>Membrane Defects        | 945 |
| Congenital Hemolytic Anemias:<br>Hemoglobinopathies               | 946 |
| Congenital Hemolytic Anemias:<br>Disorders of Red Cell Metabolism | 953 |
| Acquired Hemolytic Anemia   | 955 |
| Polycythemia & Methemoglobinemia                                  | 957 |
| Congenital Erythrocytosis<br>(Familial Polycythemia)              | 957 |
| Secondary Polycythemia  | 957 |
| Methemoglobinemia   | 957 |
| Disorders of Leukocytes   | 958 |
| Neutropenia   | 958 |
| Neutrophilia  | 960 |
| Disorders of Neutrophil Function                                  | 960 |
| Lymphocytosis   | 962 |
| Eosinophilia  | 963 |
| Bleeding Disorders  | 963 |
| Abnormalities of Platelet Number<br>or Function                   | 964 |
| Inherited Bleeding Disorders                                      | 968 |
| Von Willebrand Disease  | 972 |
| Acquired Bleeding Disorders                                       | 973 |
| Vascular Abnormalities Associated<br>with Bleeding                | 976 |
| Thrombotic Disorders  | 977 |
| Splenic Abnormalities   | 980 |
| Splenomegaly & Hypersplenism                                      | 980 |
| Asplenia & Splenectomy  | 981 |

|  |     |
|--|-----|
| Transfusion Medicine                                   | 981 |
| Donor Screening & Blood Processing:<br>Risk Management | 981 |
| Storage & Preservation of Blood & Blood<br>Components  | 981 |
| Pretransfusion Testing                                 | 986 |
| Transfusion Practice                                   | 986 |

**31. Neoplastic Disease 990***Doug K. Graham, MD, PhD, John A. Craddock, MD**Ralph R. Quinones, MD, Amy K. Keating, MD**Kelly Maloney, MD, Nicholas K. Foreman, MD, MRCP**Roger H. Giller, MD, Brian S. Greffe, MD*

|   |      |
|---|------|
| Major Pediatric Neoplastic Diseases       | 990  |
| Acute Lymphoblastic Leukemia              | 990  |
| Acute Myeloid Leukemia                    | 993  |
| Myeloproliferative Diseases               | 996  |
| Brain Tumors                              | 997  |
| Lymphomas & Lymphoproliferative Disorders | 1001 |
| Neuroblastoma                             | 1006 |
| Wilms Tumor (Nephroblastoma)              | 1008 |
| Bone Tumors                               | 1010 |
| Rhabdomyosarcoma                          | 1011 |
| Retinoblastoma                            | 1013 |
| Hepatic Tumors                            | 1014 |
| Langerhans Cell Histiocytosis             | 1015 |
| Hematopoietic Stem Cell Transplant        | 1016 |
| General Considerations                    | 1016 |
| HSCT Complications                        | 1017 |
| Late Effects of Pediatric Cancer Therapy  | 1018 |
| Growth Complications                      | 1018 |
| Endocrine Complications                   | 1019 |
| Cardiopulmonary Complications             | 1019 |
| Renal Complications                       | 1020 |
| Neuropsychological Complications          | 1020 |
| Second Malignancies                       | 1020 |

**32. Pain Management & Pediatric Palliative & End-of-Life Care 1022***Brian S. Greffe, MD**Jeffrey L. Galinkin, MD, FAAP**Nancy A. King, MSN, RN, CPNP*

|   |      |
|---|------|
| Pain Assessment   | 1022 |
| Acute Pain  | 1022 |
| Chronic Pain Management   | 1024 |
| Pediatric Palliative & End-of-Life Care                                       | 1026 |
| Introduction  | 1026 |
| Children Who May Benefit From<br>Palliative Care Interventions                | 1027 |
| Pain Management in Pediatric Palliative Care                                  | 1027 |
| Quality-of-Life Adjuncts & Symptom<br>Management in Pediatric Palliative Care | 1027 |

|   |      |
|---|------|
| Psychosocial Aspects of Pediatric Palliative Care | 1029 |
| Children's Concept of Death                       | 1029 |
| Spiritual & Cultural Support                      | 1029 |
| Withdrawal of Medical Life Support                | 1029 |
| Advance Care Planning                             | 1031 |

### 33. Immunodeficiency 1033

*Pia J. Hauk, MD*

*Richard B. Johnston, Jr, MD*

*Andrew H. Liu, MD*

|                                  |      |
|----------------------------------|------|
| Immunodeficiency Evaluation:     |      |
| Primary Considerations           | 1033 |
| Antibody Deficiency Syndromes    | 1038 |
| Severe Combined                  |      |
| Immunodeficiency Diseases        | 1042 |
| Other Combined                   |      |
| Immunodeficiency Disorders       | 1044 |
| Phagocyte Disorders              | 1047 |
| Complement Deficiencies          | 1048 |
| Other Well-Defined               |      |
| Immunodeficiency Syndromes       | 1050 |
| Genetic Syndromes                |      |
| Associated with Immunodeficiency | 1052 |

### 34. Endocrine Disorders 1054

*Philip S. Zeitler, MD, PhD*

*Sharon H. Travers, MD*

*Kristen Nadeau, MD*

*Jennifer M. Barker, MD*

*Megan Moriarty Kelsey, MD*

*Michael S. Kappy, MD, PhD*

|  |      |
|--|------|
| General Concepts                                       | 1054 |
| Hormone Types  | 1054 |
| Feedback Control of Hormone Secretion                  | 1055 |
| Disturbances of Growth                                 | 1056 |
| Target Height & Skeletal Maturation                    | 1056 |
| Short Stature  | 1056 |
| Tall Stature   | 1063 |
| Disorders of the Posterior Pituitary Gland             | 1063 |
| Arginine Vasopressin (Antidiuretic Hormone) Physiology | 1063 |
| Central Diabetes Insipidus                             | 1064 |
| Thyroid Gland  | 1065 |
| Fetal Development of the Thyroid                       | 1065 |
| Physiology   | 1065 |
| Hypothyroidism (Congenital & Acquired)                 | 1065 |
| Thyroiditis  | 1067 |
| Hyperthyroidism  | 1068 |
| Thyroid Cancer   | 1070 |
| Disorders of Calcium & Phosphorus Metabolism           | 1071 |

|   |      |
|---|------|
| Hypocalcemic Disorders  | 1071 |
| Pseudohypoparathyroidism (Resistance to Parathyroid Hormone Action)                         | 1075 |
| Hypercalcemic States  | 1075 |
| Familial Hypocalciuric Hypercalcemia (Familial Benign Hypercalcemia)                        | 1077 |
| Hypervitaminosis D  | 1077 |
| Idiopathic Hypercalcemia of Infancy (Williams Syndrome)                                     | 1077 |
| Immobilization Hypercalcemia  | 1077 |
| Hypophosphatasia  | 1077 |
| Gonads (Ovaries & Testes)   | 1078 |
| Development & Physiology  | 1078 |
| Disorders of Sexual Development   | 1078 |
| Abnormalities in Female Pubertal Development & Ovarian Function                             | 1081 |
| Abnormalities in Male Pubertal Development & Testicular Function                            | 1084 |
| Adrenal Cortex  | 1086 |
| Adrenocortical Insufficiency (Adrenal Crisis, Addison Disease)                              | 1087 |
| Congenital Adrenal Hyperplasias   | 1089 |
| Adrenocortical Hyperfunction (Cushing Disease, Cushing Syndrome)                            | 1091 |
| Primary Hyperaldosteronism  | 1093 |
| Uses of Glucocorticoids & Adrenocorticotropic Hormone in Treatment of Nonendocrine Diseases | 1093 |
| Adrenal Medulla Pheochromocytoma  | 1095 |

### 35. Diabetes Mellitus 1097

*Marian Rewers, MD, PhD*

*H. Peter Chase, MD*

|                        |      |
|------------------------|------|
| General Considerations | 1097 |
|------------------------|------|

### 36. Inborn Errors of Metabolism 1106

*Janet A. Thomas, MD*

*Johan L.K. Van Hove, MD, PhD, MBA*

|  |      |
|--|------|
| Diagnosis                                    | 1106 |
| Suspecting Inborn Errors                     | 1106 |
| Laboratory Studies                           | 1107 |
| Common Clinical Situations                   | 1107 |
| Management of Metabolic Emergencies          | 1110 |
| Newborn Screening                            | 1110 |
| Disorders of Carbohydrate Metabolism         | 1111 |
| Glycogen Storage Diseases                    | 1111 |
| Galactosemia                                 | 1112 |
| Hereditary Fructose Intolerance              | 1113 |
| Disorders of Energy Metabolism               | 1113 |
| Disorders of Amino Acid Metabolism           | 1115 |
| Disorders of the Urea Cycle                  | 1115 |
| Phenylketonuria & The Hyperphenylalaninemias | 1116 |

|  |      |
|--|------|
| Hereditary Tyrosinemia   | 1117 |
| Maple Syrup Urine Disease<br>(Branched-Chain Ketoaciduria)         | 1118 |
| Homocystinuria   | 1118 |
| Nonketotic Hyperglycinemia   | 1119 |
| Organic Acidemias  | 1120 |
| Propionic & Methylmalonic Acidemia<br>(Ketotic Hyperglycinemias)   | 1120 |
| Isovaleric Acidemia  | 1122 |
| Carboxylase Deficiency   | 1122 |
| Glutaric Acidemia Type I   | 1122 |
| Disorders of Fatty Acid Oxidation<br>& Carnitine                   | 1123 |
| Fatty Acid Oxidation Disorders                                     | 1123 |
| Carnitine  | 1124 |
| Purine Metabolism Disorders  | 1125 |
| Lysosomal Diseases   | 1125 |
| Peroxisomal Diseases   | 1129 |
| Congenital Disorders of Glycosylation                              | 1129 |
| Smith-Lemli-Opitz Syndrome & Disorders of<br>Cholesterol Synthesis | 1130 |
| Disorders of Neurotransmitter Metabolism                           | 1131 |
| Creatine Synthesis Disorders                                       | 1132 |
| Quality Initiatives in the Field of Metabolic<br>Disease           | 1132 |

### 37. Genetics & Dysmorphology 1134

|  |      |
|--|------|
| <i>Margarita Saenz, MD</i>                       |      |
| <i>Anne Chun-Hui Tsai, MD, MSc</i>               |      |
| <i>David K. Manchester, MD</i>                   |      |
| <i>Ellen R. Elias, MD</i>                        |      |
| Foundations of Genetic Diagnosis                 | 1134 |
| Cytogenetics                                     | 1134 |
| Molecular Genetics                               | 1140 |
| Principles of Inherited Human Disorders          | 1142 |
| Mendelian Inheritance                            | 1142 |
| Multifactorial Inheritance                       | 1146 |
| Nonmendelian Inheritance                         | 1147 |
| Family History & Pedigree                        | 1148 |
| Dysmorphology & Human Embryology                 | 1149 |
| Mechanisms                                       | 1149 |
| Clinical Dysmorphology                           | 1150 |
| Chromosomal Disorders: Abnormal Number           | 1151 |
| Trisomies  | 1151 |
| Sex Chromosome Abnormalities                     | 1153 |
| Chromosomal Abnormalities:<br>Abnormal Structure | 1154 |
| Chromosome Deletion Disorders                    | 1155 |
| Contiguous Gene Disorders                        | 1155 |
| Mendelian Disorders                              | 1156 |
| Autosomal Dominant Disorders                     | 1156 |
| Autosomal Recessive Disorders                    | 1159 |
| X-Linked Disorders                               | 1160 |
| Nonmendelian Disorders                           | 1161 |

|  |      |
|--|------|
| Disorders of Imprinting  | 1161 |
| Disorders Associated with Anticipation                             | 1162 |
| Mitochondrial Disorders  | 1162 |
| Disorders of Multifactorial Inheritance                            | 1163 |
| Cleft Lip & Cleft Palate   | 1163 |
| Neural Tube Defects  | 1164 |
| Common Recognizable Disorders with<br>Variable or Unknown Cause    | 1165 |
| Genetic Evaluation of the Child with<br>Developmental Disabilities | 1167 |
| Perinatal Genetics   | 1168 |
| Teratogens   | 1168 |
| Assisted Reproduction  | 1169 |
| Prenatal Diagnosis   | 1169 |

### 38. Allergic Disorders 1171

|   |      |
|---|------|
| <i>Ronina A. Covar, MD</i>                  |      |
| <i>David M. Fleischer, MD</i>               |      |
| <i>Christine Cho, MD</i>                    |      |
| <i>Mark Boguniewicz, MD</i>                 |      |
| Asthma                                      | 1171 |
| Allergic Rhinoconjunctivitis                | 1186 |
| Atopic Dermatitis                           | 1190 |
| Urticaria & Angioedema                      | 1194 |
| Anaphylaxis                                 | 1196 |
| Adverse Reactions to Drugs<br>& Biologicals | 1199 |
| Food Allergy                                | 1203 |
| Insect Allergy                              | 1205 |

### 39. Antimicrobial Therapy 1207

|  |      |
|--|------|
| <i>John W. Ogle, MD</i>  |      |
| Principles of Antimicrobial Therapy                              | 1207 |
| Antimicrobial Susceptibility Testing                             | 1208 |
| Alteration of Dose & Measurement<br>of Blood Levels              | 1212 |
| The Use of New Antimicrobial Agents                              | 1215 |
| Prophylactic Antimicrobial Agents                                | 1216 |
| Initial Empiric Antimicrobial Choices<br>for Selected Conditions | 1217 |
| Specific Antimicrobial Agents                                    | 1219 |
| Penicillins  | 1219 |
| Glycopeptide Agents  | 1221 |
| Oxazolidinones   | 1221 |
| Quinupristin-Dalfopristin  | 1221 |
| Cephalosporins   | 1222 |
| Aztreonam  | 1222 |
| Carbapenems  | 1222 |
| Macrolides & Azalides  | 1223 |
| Clindamycin  | 1223 |
| Sulfonamides   | 1223 |
| Tetracyclines  | 1224 |
| Aminoglycosides  | 1224 |



|                  |      |
|------------------|------|
| Fluoroquinolones | 1225 |
| Metronidazole    | 1225 |
| Daptomycin       | 1225 |

#### 40. Infections: Viral & Rickettsial 1227

*Myron J. Levin, MD*  
*Adriana Weinberg, MD*

|  |      |
|--|------|
| Viral Infections                               | 1227 |
| Respiratory Infections                         | 1227 |
| Viruses Causing the Common Cold                | 1227 |
| Infections Due to Adenoviruses                 | 1233 |
| Influenza                                      | 1234 |
| Parainfluenza (Croup)                          | 1236 |
| Respiratory Syncytial Virus Disease            | 1236 |
| Human Metapneumovirus Infection                | 1238 |
| Infections Due to Enteroviruses                | 1239 |
| Acute Febrile Illness                          | 1239 |
| Respiratory Tract Illnesses                    | 1239 |
| Rashes (Including Hand-Foot-and-Mouth Disease) | 1240 |
| Central Nervous System Illnesses               | 1241 |
| Infections Due to Herpesviruses                | 1243 |
| Herpes Simplex Infections                      | 1243 |
| Varicella & Herpes Zoster                      | 1246 |
| Roseola Infantum (Exanthem Subitum)            | 1249 |
| Cytomegalovirus Infections                     | 1250 |
| Infectious Mononucleosis (Epstein-Barr Virus)  | 1253 |
| Viral Infections Spread by Insect Vectors      | 1255 |
| Encephalitis                                   | 1255 |
| Dengue   | 1255 |
| Colorado Tick Fever                            | 1259 |
| Other Major Viral Childhood Exanthems          | 1259 |
| Erythema Infectiosum                           | 1259 |
| Measles (Rubeola)                              | 1261 |
| Rubella  | 1262 |
| Infections Due to Other Viruses                | 1264 |
| Hantavirus Cardiopulmonary Syndrome            | 1264 |
| Mumps  | 1265 |
| Rabies   | 1266 |
| Rickettsial Infections                         | 1267 |
| Human Ehrlichiosis                             | 1267 |
| Rocky Mountain Spotted Fever                   | 1268 |
| Endemic Typhus (Murine Typhus)                 | 1269 |
| Q Fever  | 1270 |

#### 41. Human Immunodeficiency Virus Infection 1271

*Elizabeth J. McFarland, MD*

|                                |      |
|--------------------------------|------|
| Perinatally HIV-Exposed Infant | 1273 |
| Acute Retroviral Syndrome      | 1274 |
| Progressive HIV Disease        | 1274 |
| Prevention                     | 1281 |

#### 42. Infections: Bacterial & Spirochetal 1283

*John W. Ogle, MD*  
*Marsha S. Anderson, MD*

|   |      |
|---|------|
| Bacterial Infections  | 1283 |
| Group A Streptococcal Infections  | 1283 |
| Group B Streptococcal Infections  | 1287 |
| Streptococcal Infections with Organisms other than Group A or B   | 1293 |
| Pneumococcal Infections   | 1294 |
| Staphylococcal Infections   | 1298 |
| Meningococcal Infections  | 1303 |
| Gonococcal Infections   | 1305 |
| Botulism  | 1308 |
| Tetanus   | 1310 |
| Gas Gangrene  | 1312 |
| Diphtheria  | 1313 |
| Infections Due to Enterobacteriaceae  | 1315 |
| <i>Pseudomonas</i> Infections   | 1317 |
| <i>Salmonella</i> Gastroenteritis   | 1318 |
| Typhoid Fever & Paratyphoid Fever   | 1320 |
| Shigellosis (Bacillary Dysentery)   | 1322 |
| Cholera   | 1323 |
| <i>Campylobacter</i> Infection  | 1325 |
| Tularemia   | 1326 |
| Plague  | 1327 |
| <i>Haemophilus Influenzae</i> Type B Infections   | 1328 |
| Pertussis (Whooping Cough)  | 1331 |
| Listeriosis   | 1333 |
| Tuberculosis  | 1335 |
| Infections with Nontuberculous Mycobacteria   | 1338 |
| Legionella Infection  | 1339 |
| <i>Chlamydophila</i> Infections (Psittacosis [Ornithosis], <i>C. Pneumoniae</i> & <i>C. Trachomatis</i> ) | 1341 |
| Cat-Scratch Disease   | 1343 |
| Spirochetal Infections  | 1344 |
| Syphilis  | 1344 |
| Relapsing Fever   | 1348 |
| Leptospirosis   | 1349 |
| Lyme Disease  | 1350 |

#### 43. Infections: Parasitic & Mycotic 1353

*Kevin Messacar, MD*  
*Samuel R. Dominguez, MD, PhD*  
*Myron J. Levin, MD*

|                             |      |
|-----------------------------|------|
| Parasitic Infections        | 1353 |
| Protozoal Infections        | 1357 |
| Systemic Infections         | 1357 |
| Gastrointestinal Infections | 1369 |
| Trichomoniasis              | 1374 |
| Metazoal Infections         | 1374 |
| Nematode Infections         | 1374 |

|  |      |
|--|------|
| Cestode Infections (Flukes)                                      | 1380 |
| Trematode Infections   | 1383 |
| <i>Pneumocystis</i> and Other Opportunistic<br>Fungal Infections | 1395 |
| <i>Pneumocystis jiroveci</i> Infection                           | 1397 |

#### 44. Sexually Transmitted Infections 1400

|  |      |
|--|------|
| <i>Daniel H. Reirden, MD</i>   |      |
| <i>Ann-Christine Nyquist, MD, MSPH</i>                                   |      |
| Adolescent Sexuality   | 1400 |
| Risk Factors   | 1401 |
| Prevention of Sexually<br>Transmitted Infections                         | 1401 |
| Screening For Sexually<br>Transmitted Infections                         | 1402 |
| Signs & Symptoms   | 1402 |
| The Most Common Antibiotic-responsive<br>Sexually Transmitted Infections | 1403 |
| <i>Chlamydia trachomatis</i> Infection                                   | 1403 |
| <i>Neisseria gonorrhoeae</i> Infection                                   | 1409 |
| The Spectrum of Signs & Symptoms<br>of Sexually Transmitted Infections   | 1410 |
| Cervicitis   | 1410 |
| Pelvic Inflammatory Disease  | 1410 |
| Urethritis   | 1412 |
| Epididymitis   | 1412 |
| Proctitis, Proctocolitis, & Enteritis                                    | 1413 |
| Vaginal Discharge  | 1413 |
| Genital Ulcerations  | 1415 |
| Genital Warts & Human Papillomavirus                                     | 1419 |
| Other Viral Infections   | 1420 |
| Ectoparasitic Infections   | 1422 |

#### 45. Travel Medicine 1423

|  |      |
|--|------|
| <i>Suchitra Rao, MBBS</i>                                      |      |
| <i>Sarah K. Parker, MD</i>                                     |      |
| Introduction   | 1423 |
| Preparing Children and Infants for Travel                      | 1423 |
| Vaccinations—Routine Childhood Vaccines<br>Modified for Travel | 1425 |
| Vaccinations—Travel-Specific                                   | 1427 |
| Traveler's Diarrhea  | 1429 |
| Malaria Prophylaxis & Prevention                               | 1430 |
| Visits to Friends & Relatives (VFR)<br>in High-Risk Areas      | 1431 |
| HIV & Sexually Transmitted Diseases                            | 1434 |
| Fever in the Returned Traveler                                 | 1434 |

#### 46. Chemistry & Hematology Reference Intervals 1439

|   |      |
|---|------|
| <i>Georgette Siparsky, PhD</i>  |      |
| <i>Frank J. Accurso, MD</i>   |      |
| Challenges in Determining & Interpreting<br>Pediatric Reference Intervals | 1439 |
| Guidelines for Use of Data in a Reference<br>Range Study                  | 1439 |
| Statistical Computation of Reference<br>Intervals                         | 1440 |
| Why Reference Intervals Vary  | 1441 |
| Sensitivity & Specificity   | 1442 |
| Pediatric Reference Intervals   | 1442 |
| Index   | 1455 |

# Authors

## Frank Accurso, MD

Professor, Department of Pediatrics, Head, Section of Pediatric Pulmonary Medicine, University of Colorado School of Medicine and Children's Hospital Colorado  
frank.accurso@childrenscolorado.org  
*Chapter 46: Chemistry & Hematology Reference Intervals*

## Daniel R. Ambruso, MD

Professor, Department of Pediatrics, University of Colorado School of Medicine, Associate Medical Director, Belle Bonfils Blood Center  
daniel\_ambruso@bonfils.org  
*Chapter 30: Hematologic Disorders*

## Marsha S. Anderson, MD

Associate Professor, Department of Pediatrics, Section of Pediatric Infectious Diseases, University of Colorado School of Medicine and Children's Hospital Colorado  
marsha.anderson@childrenscolorado.org  
*Chapter 42: Infections: Bacterial & Spirochetal*

## Christopher D. Baker, MD

Assistant Professor, Department of Pediatrics, Section of Pediatric Pulmonary Medicine, University of Colorado School of Medicine and Children's Hospital Colorado  
christopher.baker@ucdenver.edu  
*Chapter 19: Respiratory Tract & Mediastinum*

## Vivek Balasubramaniam, MD

Assistant Professor, Department of Pediatrics, Section of Pediatric Pulmonary Medicine, Director, Pediatric Heart Lung Center Laboratory, University of Colorado School of Medicine and Children's Hospital Colorado  
vivek.balasubramaniam@ucdenver.edu  
*Chapter 19: Respiratory Tract & Mediastinum*

## Jennifer M. Barker MD

Assistant Professor, Department of Pediatrics, Section of Pediatric Endocrinology, University of Colorado School of Medicine and Children's Hospital Colorado  
jennifer.barker@ucdenver.edu  
*Chapter 34: Endocrine Disorders*

## Mark Boguniewicz, MD

Professor, Department of Pediatrics, Section of Pediatric Allergy and Clinical Immunology, University of Colorado School of Medicine, Department of Clinical Immunology, National Jewish Health  
boguniewicz@njhealth.org  
*Chapter 38: Allergic Disorders*

## Rebecca Sands Braverman, MD

Assistant Professor, Department of Ophthalmology, University of Colorado School of Medicine and Eye Clinic, Children's Hospital Colorado  
rebecca.sandsbraverman@ucdenver.edu  
*Chapter 16: Eye*

## David Brumbaugh, MD

Assistant Professor, Department of Pediatrics, Section of Pediatric Gastroenterology, Hepatology and Nutrition, University of Colorado School of Medicine and Children's Hospital Colorado  
david.brumbaugh@childrenscolorado.org  
*Chapter 21: Gastrointestinal Tract*

## Maya Bunik, MD, MSPH

Associate Professor, Department of Pediatrics, Section of General Academic Pediatrics, Child Health Clinic, University of Colorado School of Medicine and Children's Hospital Colorado  
maya.bunik@childrenscolorado.org  
*Chapter 9: Ambulatory & Office Pediatrics*

## Adam Burnstein, DO

House Staff, Psychiatry Residency Training Program, Department of Psychiatry, University of Colorado School of Medicine and Children's Hospital Colorado  
adam.burnstein@ucdenver.edu  
*Chapter 7: Child & Adolescent Psychiatric Disorders & Psychosocial Aspects of Pediatrics*

## Brendan Caprio, BS

Research Assistant, Department of Orthopedic Surgery, University of Colorado School of Medicine, Orthopedic Institute/Musculoskeletal Research Center, Children's Hospital Colorado  
capriobf@mail.uc.edu  
*Chapter 26: Orthopedics*

## Todd C. Carpenter, MD

Associate Professor, Department of Pediatrics, Section of Pediatric Critical Care Medicine, University of Colorado School of Medicine and Children's Hospital Colorado  
todd.carpenter@ucdenver.edu  
*Chapter 14: Critical Care*

**H. Peter Chase, MD**

Professor, Department of Pediatrics, Clinical Director Emeritus, Barbara Davis Center for Childhood Diabetes  
University of Colorado School of Medicine and Children's Hospital Colorado  
peter.chase@ucdenver.edu  
*Chapter 35: Diabetes Mellitus*

**Antonia Chiesa, MD**

Senior Instructor, Department of Pediatrics, University of Colorado School of Medicine, Kempe Child Protection Team, Kempe Center for the Prevention and Treatment of Child Abuse and Neglect and Children's Hospital Colorado  
antonia.chiesa@childrenscolorado.org  
*Chapter 8: Child Abuse & Neglect*

**Christine Cho, MD**

Assistant Professor, Section of Allergy & Clinical Immunology, Department of Pediatrics, National Jewish Hospital (Primary Appointment), University of Colorado School of Medicine and Children's Hospital Colorado  
chrisbcho@gmail.com  
*Chapter 38: Allergic Disorders*

**Gerald H. Clayton, PhD**

Instructor, Department of Physical Medicine and Rehabilitation, University of Colorado School of Medicine and Children's Hospital Colorado  
jerry.clayton@ucdenver.edu  
*Chapter 28: Rehabilitation Medicine*

**Rachel A. Coel, MD, PhD, FAAP, CAQSM**

Assistant Professor, Department of Orthopedics, Co-Medical Director, Sports Medicine Program, University of Colorado School of Medicine and Children's Hospital Colorado  
rachel.coel@childrenscolorado.org  
*Chapter 27: Sports Medicine*

**Kathryn K. Collins, MD**

Associate Professor, Department of Pediatrics, Section of Pediatric Cardiology, University of Colorado School of Medicine and Children's Hospital Colorado  
kathryn.collins@childrenscolorado.org  
*Chapter 20: Cardiovascular Diseases*

**Ronina A. Covarr, MD**

Associate Professor, Department of Pediatrics, Section of Pediatric Allergy and Clinical Immunology, University of Colorado School of Medicine, and National Jewish Health  
covarr@njhealth.org  
*Chapter 38: Allergic Disorders*

**John A. Craddock, MD**

Assistant Professor, Department of Pediatrics, Section of Pediatric Hematology/Oncology/Bone Marrow Transplant, Center for Cancer/Blood Disorders, University of Colorado School of Medicine and Children's Hospital Colorado  
john.craddock@childrenscolorado.org  
*Chapter 31: Neoplastic Disease*

**Angela S. Czaja, MD, MSc**

Assistant Professor, Department of Pediatrics, Section of Pediatric Critical Care Medicine, University of Colorado School of Medicine and Children's Hospital Colorado  
angela.czaja@childrenscolorado.org  
*Chapter 14: Critical Care*

**Matthew F. Daley, MD**

Assistant Professor, Department of Pediatrics, Section of General Academic Pediatrics, University of Colorado School of Medicine and Children's Hospital Colorado, Senior Investigator, Institute for Health Research, Kaiser Permanente Colorado  
matthew.f.daley@kp.org  
*Chapter 10: Immunization*

**Jeffrey R. Darst, MD**

Assistant Professor, Department of Pediatrics, Section of General Academic Pediatrics, University of Colorado School of Medicine and Children's Hospital Colorado  
jeffrey.darst@ucdenver.edu  
*Chapter 20: Cardiovascular Diseases*

**Richard C. Dart, MD, PhD**

Professor, Department of Surgery, Director, Rocky Mountain Poison and Drug Center, Denver Health and Hospital Authority, University of Colorado School of Medicine  
rdart@rmpdc.org  
*Chapter 13: Poisoning*

**Emily M. Deboer, MD**

Instructor, Department of Pediatrics, Section of Pediatric Pulmonary Medicine, University of Colorado School of Medicine and Children's Hospital Colorado  
emily.deboer@childrenscolorado.org  
*Chapter 19: Respiratory Tract & Mediastinum*

**Robin R. Deterding, MD**

Professor, Department of Pediatrics, Section of Pediatric Pulmonary Medicine, University of Colorado School of Medicine and Children's Hospital Colorado  
Medical Director, Breathing Institute  
Children's Hospital Colorado  
robin.deterding@childrenscolorado.org  
*Chapter 19: Respiratory Tract & Mediastinum*

**Samuel R. Dominguez, MD, PhD**

Assistant Professor, Department of Pediatrics, Section of Pediatric Infectious Diseases, University of Colorado School of Medicine and Children's Hospital Colorado  
samuel.dominguez@ucdenver.edu  
*Chapter 43: Infections: Parasitic & Mycotic*

**Ellen R. Elias, MD**

Professor, Departments of Pediatrics and Genetics, Section of Clinical Genetics and Metabolism, University of Colorado School of Medicine, Director, Special Care Clinic, Children's Hospital Colorado  
ellen.elias@childrenscolorado.org  
*Chapter 37: Genetics & Dysmorphology*

**Mark A. Erickson, MD, MMM**

Associate Professor, Department of Orthopedic Surgery, University of Colorado School of Medicine, Chairman, Department of Pediatric Orthopedics, Orthopedic Institute, Children's Hospital Colorado  
mark.erickson@childrenscolorado.org  
*Chapter 26: Orthopedics*

**Jennifer Exo, DO**

Assistant Professor, Department of Pediatrics, Section of Critical Care Medicine, University of Colorado School of Medicine and Children's Hospital Colorado  
jennifer.exo@ucdenver.edu  
*Chapter 14: Critical Care*

**Monica J. Federico, MD**

Assistant Professor, Department of Pediatrics, Section of Pediatric Pulmonology Medicine, University of Colorado School of Medicine and Children's Hospital Colorado  
monica.federico@childrenscolorado.org  
*Chapter 19: Respiratory Tract & Mediastinum*

**David M. Fleischer, MD**

Assistant Professor, Department of Pediatrics, Section of Pediatric Allergy and Clinical Immunology, University of Colorado School of Medicine and National Jewish Health  
fleischerd@njhealth.org  
*Chapter 38: Allergic Disorders*

**Douglas M. Ford, MD**

Professor, Department of Pediatrics, Section of Pediatric Nephrology, Director, Home Dialysis and Renal Transplantation, University of Colorado School of Medicine and Children's Hospital Colorado  
douglas.ford@childrenscolorado.org  
*Chapter 23: Fluid, Electrolyte, & Acid-Base Disorders & Therapy*

**Nicholas K. Foreman, MD, MRCP**

Professor, Department of Pediatrics, Section of Pediatric Hematology/Oncology/Bone Marrow Transplant, Center for Cancer/Blood Disorders, Seebaum/Tschetter Chair of Neuro-Oncology, University of Colorado School of Medicine and Children's Hospital Colorado  
nicholas.foreman@childrenscolorado.org  
*Chapter 31: Neoplastic Disease*

**David Fox, MD**

Assistant Professor, Department of Pediatrics, Section of General Academic Pediatrics, University of Colorado School of Medicine and Children's Hospital Colorado  
david.fox@childrenscolorado.org  
*Chapter 9: Ambulatory & Office Pediatrics*

**Norman R. Friedman, MD**

Associate Professor, Department of Otolaryngology, University of Colorado School of Medicine and ENT Clinic, Children's Hospital Colorado  
norman.friedman@childrenscolorado.org  
*Chapter 18: Ear, Nose, & Throat*

**Glenn T. Furuta, MD**

Associate Professor, Department of Pediatrics, Section of Pediatric Gastroenterology, Hepatology and Nutrition, Director, Gastrointestinal Eosinophil Disease Program National Jewish Hospital, University of Colorado School of Medicine and Children's Hospital Colorado  
glenn.furuta@childrenscolorado.org  
*Chapter 21: Gastrointestinal Tract*

**Jeffrey L. Galinkin, MD, FAAP**

Associate Professor, Department of Anesthesiology, University of Colorado School of Medicine and Children's Hospital Colorado  
jeffrey.galinkin@ucdenver.edu  
*Chapter 32: Pain Management & Pediatric Palliative & End-of-Life Care*

**Roger H. Giller, MD**

Professor, Department of Pediatrics, Section of Pediatric Hematology/Oncology/Bone Marrow Transplant, Center for Cancer/Blood Disorders, Director, Pediatric Bone Marrow Transplant Program, University of Colorado School of Medicine and Children's Hospital Colorado  
roger.giller@childrenscolorado.org  
*Chapter 31: Neoplastic Disease*

**Edward Goldson, MD**

Professor, Department of Pediatrics, University of Colorado School of Medicine and Children's Hospital Colorado  
edward.goldson@childrenscolorado.org  
*Chapter 3: Child Development & Behavior*

**Douglas K. Graham, MD, PhD**

Associate Professor, Department of Pediatrics, Section of Pediatric Hematology/Oncology/Bone Marrow Transplant, Center for Cancer/Blood Disorders, University of Colorado School of Medicine and Children's Hospital Colorado  
doug.graham@ucdenver.edu  
*Chapter 31: Neoplastic Disease*

**Eva N. Grayck, MD**

Associate Professor, Department of Pediatrics, Section of Pediatric Critical Care Medicine, University of Colorado School of Medicine and Children's Hospital Colorado  
eva.grayck@ucdenver.edu  
*Chapter 14: Critical Care*

**Brian S. Greffe, MD**

Professor, Department of Pediatrics, Section of Pediatric Hematology/Oncology/Bone Marrow Transplant, Center for Cancer/Blood Disorders, University of Colorado School of Medicine and Children's Hospital Colorado  
brian.greffe@childrenscolorado.org  
*Chapter 31: Neoplastic Disease*  
*Chapter 32: Pain Management & Pediatric Palliative & End-of-Life Care*

**Theresa Grover, MD**

Associate Professor, Department of Pediatrics, Section of Neonatology, Medical Director, Neonatal Intensive Care Unit of Children's Hospital Colorado, University of Colorado School of Medicine and Children's Hospital Colorado  
theresa.grover@childrenscolorado.org  
*Chapter 2: The Newborn Infant*

**Joseph A. Grubenhoff, MD**

Assistant Professor, Department of Pediatrics, Section of Pediatric Emergency Medicine, University of Colorado School of Medicine and Children's Hospital Colorado  
joe.grubenhoff@childrenscolorado.org  
*Chapter 12: Emergencies & Injuries*

**Cameron F. Gunville, DO**

Assistant Professor, Department of Pediatrics, Section of Pediatric Critical Care Medicine, University of Colorado School of Medicine and Children's Hospital Colorado  
cameron.gunville@childrenscolorado.org  
*Chapter 14: Critical Care*

**Matthew A. Haemer, MD**

Assistant Professor, Department of Pediatrics, Section of Nutrition, University of Colorado School of Medicine and Children's Hospital Colorado  
matthew.haemer@childrenscolorado.org  
*Chapter 11: Normal Childhood Nutrition & Its Disorders*

**Ann Halbower, MD**

Associate Professor, Department of Pediatrics, Section of Pediatric Pulmonary Medicine, University of Colorado School of Medicine and Children's Hospital Colorado  
ann.halbower@childrenshospital.org  
*Chapter 19: Respiratory Tract & Mediastinum*

**Pia J. Hauk, MD**

Assistant Professor, Department of Pediatrics, Section of Pediatric Allergy and Clinical Immunology, University of Colorado School of Medicine and National Jewish Health  
haukp@njhealth.org  
*Chapter 33: Immunodeficiency*

**Quynh B. Hoang, MD, FAAP, CAQSM**

Assistant Professor, Department of Orthopedics, Sports Medicine Program, University of Colorado School of Medicine and Children's Hospital Colorado  
quynh.b.hoang@ucdenver.edu  
*Chapter 27: Sports Medicine*

**Edward J. Hoffenberg, MD**

Associate Professor, Department of Pediatrics, Section of Pediatric Gastroenterology, Hepatology and Nutrition, University of Colorado School of Medicine and Children's Hospital Colorado  
edward.hoffenberg@childrenscolorado.org  
*Chapter 21: Gastrointestinal Tract*

**Daniel Hyman, MD, MMM**

Chief Quality Officer, Children's Hospital Colorado, Department of Pediatrics, Section of Pediatric Administration, University of Colorado School of Medicine and Children's Hospital Colorado  
daniel.hyman@childrenscolorado.org  
*Chapter 1: Advancing the Quality & Safety of Care*

**Richard B. Johnston Jr., MD**

Professor, Department of Pediatrics, Section of Allergy and Clinical Immunology, Associate Dean for Research Development, University of Colorado School of Medicine and National Jewish Health  
richard.johnston@ucdenver.edu  
*Chapter 33: Immunodeficiency*

**David W. Kaplan, MD, MPH**

Professor, Department of Pediatrics, Head, Section of Adolescent Medicine, University of Colorado School of Medicine and Children's Hospital Colorado  
david.kaplan@childrenscolorado.org  
*Chapter 4: Adolescence*

**Michael S. Kappy, MD, PhD**

Professor, Department of Pediatrics, Head, Section of Pediatric Endocrinology, University of Colorado School of Medicine and Children's Hospital Colorado  
 michael.kappy@childrenscolorado.org  
*Chapter 34: Endocrine Disorders*

**Paritosh Kaul, MD**

Associate Professor, Department of Pediatrics, Section of Adolescent Medicine, University of Colorado School of Medicine, Denver Health and Children's Hospital Colorado  
 paritosh.kaul@childrenscolorado.org  
*Chapter 5: Adolescent Substance Abuse*

**Amy K. Keating, MD**

Assistant Professor, Department of Pediatrics, Section of Pediatric Hematology/Oncology/Bone Marrow Transplant, Center for Cancer/Blood Disorders, University of Colorado School of Medicine and Children's Hospital Colorado  
 amy.keating@ucdenver.edu  
*Chapter 31: Neoplastic Disease*

**Sita Kedia, MD**

Assistant Professor, Departments of Pediatrics and Neurology, Section of Pediatric Neurology, University of Colorado School of Medicine and Children's Hospital Colorado  
 sita.kedia@ucdenver.edu  
*Chapter 25: Neurologic & Muscular Disorders*

**Kimberly Kelsay, MD**

Associate Professor, Department of Psychiatry, Division of Child and Adolescent Psychiatry, University of Colorado School of Medicine, Department of Psychiatry and Behavioral Sciences, Children's Hospital Colorado  
*Chapter 7: Child & Adolescent Psychiatric Disorders & Psychosocial Aspects of Pediatrics*

**Megan Moriarty Kelsey, MD**

Instructor, Department of Pediatrics, Section of Pediatric Endocrinology, University of Colorado School of Medicine and Children's Hospital Colorado  
 megan.kelsey@childrenscolorado.org  
*Chapter 34: Endocrine Disorders*

**Nancy A. King, MSN, RN, CPNP**

Senior Instructor, Department of Pediatrics, Section of Pediatric Hematology/Oncology/Bone Marrow Transplant, Center for Cancer/Blood Disorder, University of Colorado School of Medicine and Children's Hospital Colorado  
 nancy.king@childrenscolorado.org  
*Chapter 32: Pain Management & Pediatric Palliative & End-of-Life Care*

**Ulrich Klein, DMD, DDS, MS**

Associate Professor, Chair, Department of Pediatric Dentistry, University of Colorado School of Dental Medicine and Children's Hospital Colorado  
 ulric.klein@childrenscolorado.org  
*Chapter 17: Oral Medicine & Dentistry*

**Kelly Knupp, MD**

Assistant Professor, Departments of Pediatrics and Neurology, Section of Pediatric Neurology, University of Colorado School of Medicine and Children's Hospital Colorado  
 kelly.knupp@childrenscolorado.org  
*Chapter 25: Neurologic & Muscular Disorders*

**Gregg Kobak, MD**

Senior Instructor of Pediatrics, Section of Pediatric Gastroenterology, Hepatology and Nutrition, Digestive Health Institute, University of Colorado School of Medicine  
 gregory.kobak@childrenscolorado.org  
*Chapter 21: Gastrointestinal Tract*

**Robert E. Kramer, MD**

Assistant Professor, Department of Pediatrics, Section of Pediatric Gastroenterology, Hepatology and Nutrition, University of Colorado School of Medicine and Children's Hospital Colorado  
 robert.kramer@childrenscolorado.org  
*Chapter 21: Gastrointestinal Tract*

**Nancy F. Krebs, MD, MS**

Professor, Department of Pediatrics, Head, Section of Pediatric Nutrition, University of Colorado School of Medicine and Children's Hospital Colorado  
 nancy.krebs@ucdenver.edu  
*Chapter 11: Normal Childhood Nutrition & Its Disorders*

**Orten Kupfer, MD**

Fellow, Department of Pediatrics, Section of Pediatric Pulmonary Medicine, University of Colorado School of Medicine and Children's Hospital Colorado  
 oren.kupfer@childrenscolorado.org  
*Chapter 19: Respiratory Tract & Mediastinum*

**Myron J. Levin, MD**

Professor, Departments of Pediatrics and Medicine, Section of Pediatric Infectious Diseases, University of Colorado School of Medicine and Children's Hospital Colorado  
 myron.levin@ucdenver.edu  
*Chapter 40: Infections: Viral & Rickettsial*  
*Chapter 43: Infections: Parasitic & Myotic*

**Paul M. Levisohn, MD**

Associate Professor, Departments of Pediatrics and Neurology, Section of Pediatric Neurology, University of Colorado School of Medicine and Children's Hospital Colorado  
 paul.levisohn@childrenscolorado.org  
*Chapter 25: Neurologic & Muscular Disorders*

**Andrew H. Liu, MD**

Associate Professor, Department of Pediatrics, Section of Allergy and Immunology, University of Colorado School of Medicine, National Jewish Health and Children's Hospital Colorado  
 liua@njhealth.org  
*Chapter 33: Immunodeficiency*

**Edward Liu, MD**

Associate Professor, Department of Pediatrics, Section of Pediatric Gastroenterology, Hepatology and Nutrition, Digestive Health Institute, University of Colorado School of Medicine and Children's Hospital Colorado  
edwin.liu@childrenscolorado.org  
*Chapter 21: Gastrointestinal Tract*

**Gary M. Lum, MD**

Professor, Department of Pediatrics, Head, Section of Pediatric Nephrology, University of Colorado School of Medicine and Children's Hospital Colorado  
gary.lum@childrenscolorado.org  
*Chapter 24: Kidney & Urinary Tract*

**Cara L. Mack, MD**

Associate Professor, Department of Pediatrics, Section of Pediatric Gastroenterology, Hepatology and Nutrition, University of Colorado School of Medicine, Digestive Health Institute, Children's Hospital Colorado  
cara.mack@childrenscolorado.org  
*Chapter 22: Liver & Pancreas*

**Kelly Maloney, MD**

Associate Professor, Department of Pediatrics, Section of Pediatric Hematology/Oncology/Bone Marrow Transplant, Center for Cancer/Blood Disorders, University of Colorado School of Medicine and Children's Hospital Colorado  
kelly.maloney@childrenscolorado.org  
*Chapter 31: Neoplastic Disease*

**David K. Manchester, MD**

Professor, Department of Pediatrics, Section of Clinical Genetics and Metabolism, University of Colorado School of Medicine and Children's Hospital Colorado  
david.manchester@childrenscolorado.org  
*Chapter 37: Genetics & Dysmorphology*

**Maria J. Mandt, MD**

Assistant Professor, Department of Pediatrics, Section of Pediatric Emergency Medicine, University of Colorado School of Medicine and Children's Hospital Colorado  
maria.mandt@childrenscolorado.org  
*Chapter 12: Emergencies & Injuries*

**Stacey L. Martiniano, MD**

Assistant Professor Department of Pediatrics, Section of Pediatric Pulmonary Medicine, University of Colorado School of Medicine and Children's Hospital Colorado  
stackey.martiniano@childrenscolorado.org  
*Chapter 19: Respiratory Tract & Mediastinum*

**Elizabeth J. McFarland, MD**

Professor, Department of Pediatrics, Section of Pediatric Infectious Diseases, University of Colorado School of Medicine and Children's Hospital Colorado  
betsy.mcfarland@ucdenver.edu  
*Chapter 41: Human Immunodeficiency Virus Infection*

**Kevin Messacar, MD**

Fellow, Department of Pediatrics, Section of Pediatric Infectious Diseases, University of Colorado School of Medicine and Children's Hospital Colorado  
kevin.messacar@childrenscolorado.org  
*Chapter 43: Infections: Parasitic & Mycotic*

**Shelley D. Miyamoto, MD**

Assistant Professor, Department of Pediatrics, Section of Pediatric Cardiology, University of Colorado School of Medicine and Children's Hospital Colorado  
shelley.miyamoto@childrenscolorado.org  
*Chapter 20: Cardiovascular Diseases*

**Paul G. Moe, MD**

Professor, Departments of Pediatrics and Neurology, Section of Pediatric Neurology, University of Colorado School of Medicine and Children's Hospital Colorado  
paul.moe@childrenscolorado.org  
*Chapter 25: Neurologic & Muscular Disorders*

**Joseph G. Morelli, MD**

Professor, Departments of Dermatology and Pediatrics, Head, Section of Pediatric Dermatology, University of Colorado School of Medicine and Children's Hospital Colorado  
joseph.morelli@ucdenver.edu  
*Chapter 15: Skin*

**Kristen Nadeau, MD**

Assistant Professor, Department of Pediatrics, Section of Pediatric Endocrinology, University of Colorado School of Medicine and Children's Hospital Colorado  
kristen.nadeau@ucdenver.edu  
*Chapter 34: Endocrine Disorders*

**Michael R. Narkewicz, MD**

Professor, Department of Pediatrics, Hewitt-Andrews Chair in Pediatric Liver Disease, Medical Director, The Pediatric Liver Center and Liver Transplantation Program, Section of Pediatric Gastroenterology, Hepatology and Nutrition, University of Colorado School of Medicine and Children's Hospital Colorado  
michael.narkewicz@childrenscolorado.org  
*Chapter 22: Liver & Pancreas*

**Rachelle Nuss, MD**

Professor, Department of Pediatrics, Section of Pediatric Hematology/Oncology/Bone Marrow Transplant, Sickle Cell Center, University of Colorado School of Medicine and Children's Hospital Colorado  
rachelle.nuss@childrenscolorado.org  
*Chapter 30: Hematologic Disorders*



**Ann-Christine Nyquist, MD, MSPH**

Professor, Department of Pediatrics, Section of Pediatric Infectious Diseases, University of Colorado School of Medicine and Children's Hospital Colorado  
ann-christine.nyquist@childrenscolorado.org

*Chapter 10: Immunization*

*Chapter 43: Sexually Transmitted Infections*

**John W. Ogle, MD**

Professor and Vice Chairman, Department of Pediatrics, Director, Department of Pediatrics, Denver Health and University of Colorado School of Medicine  
jogle@dhha.org

*Chapter 39: Antimicrobial Therapy*

*Chapter 42: Infections: Bacterial & Spirochetal*

**Sean T. O'Leary, MD, MPH**

Assistant Professor, Department of Pediatrics, Section of Pediatric Infectious Diseases, University of Colorado School of Medicine and Children's Hospital Colorado  
olearysea@gmail.com

*Chapter 10: Immunization*

**Sarah K. Parker, MD**

Assistant Professor, Department of Pediatrics, Section of Pediatric Infectious Diseases, University of Colorado School of Medicine and Children's Hospital Colorado  
sarah.parker@ucdenver.edu

*Chapter 45: Travel Medicine*

**Laura E. Primak, RD, CNSD, CSP**

Coordinator/Professional Research Assistant/Dietitian, Department of Pediatrics, Section of Pediatric Nutrition, University of Colorado School of Medicine and Children's Hospital Colorado

laura.primak@ucdenver.edu

*Chapter 11: Normal Childhood Nutrition & Its Disorders*

**Lori D. Prok, MD**

Assistant Professor, Departments of Pediatrics and Dermatology, Section of Pediatric Dermatology, University of Colorado School of Medicine and Children's Hospital Colorado

lori.prok@ucdenver.edu

*Chapter 15: Skin*

**Ralph R. Quinones, MD**

Associate Professor, Department of Pediatrics, Section of Pediatric Hematology/Oncology/Bone Marrow Transplant, University of Colorado School of Medicine and Children's Hospital Colorado

ralph.quinones@childrenscolorado.org

*Chapter 31: Neoplastic Disease*

**Suchitra Rao, MBBS**

Assistant Professor, Department of Pediatrics, Section of Pediatric Infectious Diseases, University of Colorado School of Medicine and Children's Hospital Colorado  
suchitra.rao@childrenscolorado.org

*Chapter 45: Travel Medicine*

**Daniel H. Reirden, MD**

Assistant Professor, Departments of Internal Medicine and Pediatrics, Sections of Adolescent Medicine and Pediatric Infectious Diseases, University of Colorado School of Medicine and Children's Hospital Colorado

daniel.reirden@childrenscolorado.org

*Chapter 44: Sexually Transmitted Infections*

**Marian Rewers, MD, PhD**

Professor and Clinical Director, Barbara Davis Center for Childhood Diabetes, University of Colorado School of Medicine and Children's Hospital Colorado

marian.rewers@ucdenver.edu

*Chapter 35: Diabetes Mellitus*

**Ann Reynolds, MD**

Assistant Professor, Department of Pediatrics, Section of Child Developmental and Behavioral Pediatrics, Director, The Child Development Unit, University of Colorado School of Medicine and Children's Hospital Colorado

ann.reynolds@childrenscolorado.org

*Chapter 3: Child Development & Behavior*

**Adam A. Rosenberg, MD**

Professor, Department of Pediatrics, Section of Neonatology, Director, Pediatrics Residency Program, University of Colorado School of Medicine and Children's Hospital Colorado

adam.rosenberg@childrenscolorado.org

*Chapter 2: The Newborn Infant*

**Barry H. Rumack, MD**

Clinical Professor, Department of Pediatrics, University of Colorado School of Medicine, Director Emeritus, Rocky Mountain Poison and Drug Center, Denver Health Authority

barry@rumack.com

*Chapter 13: Poisoning*

**Margarita Saenz, MD**

Assistant Professor, Department of Pediatrics, Section of Clinical Genetics and Metabolism, University of Colorado School of Medicine and Children's Hospital Colorado

margarita.saenz@childrenscolorado.org

*Chapter 37: Genetics & Dysmorphology*

**Scott D. Sagel, MD**

Associate Professor, Department of Pediatrics, Section of Pediatric Pulmonary Medicine, University of Colorado School of Medicine and Children's Hospital Colorado  
 scott.sagel@childrenscolorado.org  
*Chapter 19: Respiratory Tract & Mediastinum*

**Amy E. Sass, MD, MPH**

Assistant Professor, Department Pediatrics, Section of Adolescent Medicine, University of Colorado School of Medicine and Children's Hospital Colorado  
 amy.sass@childrenscolorado.org  
*Chapter 4: Adolescence*

**Melissa A. Scholes, MD**

Assistant Professor, Department of Pediatrics, Section of Pediatric Otolaryngology, University of Colorado School of Medicine and Children's Hospital Colorado  
*Chapter 18: Ear, Nose, Throat*

**Teri Schreiner, MD, MPH**

Assistant Professor, Department of Pediatrics, Section of Child Neurology, University of Colorado School of Medicine and Children's Hospital Colorado  
 teri.schreiner@childrenscolorado.org  
*Chapter 25: Neurologic & Muscular Disorders*

**Eric J. Sigel, MD**

Associate Professor, Department of Pediatrics, Section of Adolescent Medicine, University of Colorado School of Medicine and Children's Hospital Colorado  
 eric.sigel@childrenscolorado.org  
*Chapter 6: Eating Disorders*

**Georgette Siparsky, PhD**

Clinical Data Analyst, Department of Clinical Informatics, University of Colorado School of Medicine and Children's Hospital Colorado  
 georgette.siparsky@childrenscolorado.org  
*Chapter 46: Chemistry & Hematology Reference Intervals*

**Andrew P. Sirotnak, MD**

Professor and Vice Chair for Faculty Affairs, Department of Pediatrics, University of Colorado School of Medicine, Director, Child Protection Team, Children's Hospital Colorado, Kempe Center for the Prevention and Treatment of Child Abuse and Neglect  
 andrew.sirotnak@childrenscolorado.org  
*Chapter 8: Child Abuse & Neglect*

**Jason Soden, MD**

Assistant Professor, Department of Pediatrics, Section of Pediatric Gastroenterology, Hepatology and Nutrition, University of Colorado School of Medicine and Children's Hospital Colorado  
 jason.soden@childrenscolorado.org  
*Chapter 21: Gastrointestinal Tract*

**Jennifer B. Soep, MD**

Assistant Professor, Department of Pediatrics, Section of Pediatric Rheumatology, University of Colorado School of Medicine and Children's Hospital Colorado  
 jennifer.soep@childrenscolorado.org  
*Chapter 29: Rheumatic Diseases*

**Ronald J. Sokol, MD**

Professor and Vice Chair, Department of Pediatrics, Head, Section of Pediatric Gastroenterology, Hepatology and Nutrition, Director, Colorado Clinical and Translational Sciences Institute, University of Colorado School of Medicine and Children's Hospital Colorado  
 ronald.sokol@childrenscolorado.org  
*Chapter 22: Liver & Pancreas*

**Brian Stafford, MD, MPH**

Assistant Professor, Departments of Psychiatry and Pediatrics, University of Colorado School of Medicine and Children's Hospital Colorado  
 brian.stafford@childrenscolorado.org  
*Chapter 7: Child & Adolescent Psychiatric Disorders & Psychosocial Aspects of Pediatrics*

**Paul Stillwell, MD**

Senior Instructor, Department of Pediatrics, Section of Pediatric Pulmonary Medicine, University of Colorado School of Medicine and Children's Hospital Colorado  
 paul.stillwell@childrenscolorado.org  
*Chapter 19: Respiratory Tract & Mediastinum*

**Shikha S. Sundaram, MD, MSCI**

Assistant Professor, Department of Pediatrics, Section of Pediatric Gastroenterology, Hepatology and Nutrition University of Colorado School of Medicine and Children's Hospital Colorado  
 shikha.sundaram@childrenscolorado.org  
*Chapter 22: Liver & Pancreas*

**Ayelet Talmi, PhD**

Assistant Professor, Departments of Psychiatry and Pediatrics, Associate Director, Irving Harris Program in Child Development and Infant Mental Health, University of Colorado School of Medicine and Children's Hospital Colorado  
 talmi.ayelet@ucdenver.edu  
*Chapter 7: Child & Adolescent Psychiatric Disorders & Psychosocial Aspects of Pediatrics*

**Janet A. Thomas, MD**

Associate Professor, Department of Pediatrics, Section of Clinical Genetics and Metabolism, University of Colorado School of Medicine and Children's Hospital Colorado  
 janet.thomas@childrenscolorado.org  
*Chapter 36: Inborn Errors of Metabolism*

**Sharon H. Travers, MD**

Associate Professor, Department of Pediatrics, Section of Pediatric Endocrinology, University of Colorado School of Medicine and Children's Hospital Colorado  
sharon.travers@childrenscolorado.org  
*Chapter 34: Endocrine Disorders*

**Meghan Treitz, MD**

Assistant Professor, Department of Pediatrics, Section of General Academic Pediatrics, University of Colorado School of Medicine and Children's Hospital Colorado  
meghan.treitz@childrenscolorado.org  
*Chapter 9: Ambulatory & Community Pediatrics*

**Anne Chun-Hui Tsai, MD, Msc**

Associate Professor, Departments of Pediatrics and Genetics, Section of Clinical Genetics and Metabolism, University of Colorado School of Medicine and Children's Hospital Colorado  
chun-hui.tsai@childrenscolorado.org  
*Chapter 37: Genetics & Dysmorphology*

**Johan L. K. Van Hove, MD, PhD, MBA**

Associate Professor, Department of Pediatrics, Section of Clinical Genetics and Metabolism, University of Colorado School of Medicine and Children's Hospital Colorado  
johan.vanhove@childrenscolorado.org  
*Chapter 36: Inborn Errors of Metabolism*

**Armando Vidal, MD**

Assistant Professor, Department of Orthopedics, Sports Medicine Program, University of Colorado School of Medicine and Children's Hospital Colorado  
armando.vidal@ucdenver.edu  
*Chapter 27: Sports Medicine*

**George Sam Wang, MD**

Fellow, Rocky Mountain Poison and Drug Center, Denver Health Authority, Clinical Instructor, Department of Pediatrics, Section of Pediatric Emergency Medicine, University of Colorado School of Medicine  
george.wang2@childrenscolorado.org  
*Chapter 13: Poisoning*

**Michael Wang, MD**

Assistant Professor, Department of Pediatrics, Section of Pediatric Hematology/Oncology/Bone Marrow Transplant, Center for Cancer/Blood Disorders, University of Colorado School of Medicine and Children's Hospital Colorado  
michael.wang@ucdenver.edu  
*Chapter 30: Hematologic Disorders*

**Adriana Weinberg, MD**

Professor, Department of Pediatrics, Director, Clinical Virology Laboratory, Section of Pediatric Infectious Diseases, University of Colorado School of Medicine and Children's Hospital Colorado  
adriana.weinberg@ucdenver.edu  
*Chapter 40: Infections: Viral & Rickettsial*

**Pamela E. Wilson, MD**

Assistant Professor, Department of Rehabilitation Medicine, Rehabilitation Center, University of Colorado School of Medicine and Children's Hospital Colorado  
pamela.wilson@childrenscolorado.org  
*Chapter 28: Rehabilitation Medicine*

**Michele L. Yang, MD**

Assistant Professor, Departments of Pediatrics and Neurology, Section of Pediatric Neurology, University of Colorado School of Medicine and Children's Hospital Colorado  
michele.yang@childrenscolorado.org  
*Chapter 25: Neurologic & Muscular Disorders*

**Patricia J. Yoon, MD**

Assistant Professor, Department of Pediatrics, Section of Pediatric Otolaryngology, University of Colorado School of Medicine and Children's Hospital Colorado  
patricia.yoon@childrenscolorado.org  
*Chapter 18: Ear, Nose, & Throat*

**Carleen Zebuhr, MD**

Assistant Professor, Department of Pediatrics, Section of Pediatric Critical Care Medicine, University of Colorado School of Medicine and Children's Hospital Colorado  
carleen.zebuhr@childrenscolorado.org  
*Chapter 14: Critical Care*

**Philip S. Zeitler, MD, PhD**

Professor, Department of Pediatrics, Head, Section of Pediatric Endocrinology, University of Colorado School of Medicine and Children's Hospital Colorado  
phil.zeitler@ucdenver.edu  
*Chapter 34: Endocrine Disorders*

**Edith T. Zemanick, MD**

Assistant Professor, Department of Pediatrics, Section of Pediatric Pulmonary Medicine, University of Colorado School of Medicine and Children's Hospital Colorado  
edith.zemanick@childrenscolorado.org  
*Chapter 19: Respiratory Tract & Mediastinum*

# Preface

The 22nd edition of *Current Diagnosis & Treatment: Pediatrics (CDTP)* features practical, up-to-date, well-referenced information on the care of children from birth through infancy and adolescence. *CDTP* emphasizes the clinical aspects of pediatric care while also covering important underlying principles. *CDTP* provides a guide to diagnosis, understanding, and treatment of the medical problems of all pediatric patients in an easy-to-use and readable format.

## INTENDED AUDIENCE

Like all Lange medical books, *CDTP* provides a concise, yet comprehensive source of current information. Students will find *CDTP* an authoritative introduction to pediatrics and an excellent source for reference and review. *CDTP* provides excellent coverage of The Council on Medical Student Education in Pediatrics (COMSEP) curriculum used in pediatric clerkships. Residents in pediatrics (and other specialties) will appreciate the detailed descriptions of diseases as well as diagnostic and therapeutic procedures. Pediatricians, family practitioners, nurses and nurse practitioners, and other healthcare providers who work with infants and children will find *CDTP* a useful reference on management aspects of pediatric medicine.

## COVERAGE

Forty-six chapters cover a wide range of topics, including neonatal medicine, child development and behavior, emergency and critical care medicine, and diagnosis and treatment of specific disorders according to major problems, etiologies, and organ systems. A wealth of tables and figures provides quick access to important information, such as acute and critical care procedures in the delivery room, the office, the emergency room, and the critical care unit; anti-infective agents; drug dosages; immunization schedules; differential diagnosis; and developmental screening tests. The final chapter is a handy guide to normal laboratory values.

## NEW TO THIS EDITION

The 22nd edition of *CDTP* has been revised comprehensively by the editors and contributing authors. New references as well as up-to-date and useful Web sites have been added, permitting the reader to consult original material and to go beyond the confines of the textbook. As editors and practicing pediatricians, we have tried to ensure that each chapter reflects the needs and realities of day-to-day practice.

## CHAPTERS WITH MAJOR REVISIONS INCLUDE:

- 3 Child Development & Behavior
- 6 Eating Disorders
- 9 Ambulatory & Office Pediatrics
- 10 Immunization
- 13 Poisoning
- 14 Critical Care
- 15 Skin
- 19 Respiratory Tract & Mediastinum
- 21 Gastrointestinal Tract
- 22 Liver & Pancreas
- 25 Neurologic & Muscular Disorders
- 26 Orthopedics
- 31 Neoplastic Disease

- 32 Pain Management & Pediatric Palliative & End-of-Life Care
- 33 Immunodeficiency
- 37 Genetics & Dysmorphology
- 38 Allergic Disorders
- 39 Antimicrobial Therapy
- 40 Infections: Viral & Rickettsial
- 41 Human Immunodeficiency Virus Infection
- 42 Infections: Bacterial & Spirochetal
- 43 Infections: Parasitic & Mycotic

## CHAPTER REVISIONS

The 22 chapters that have been extensively revised, with new authors added in several cases, reflect the substantially updated material in each of their areas of pediatric medicine. Especially important are updates to the chapters on immunizations, diabetes, and endocrinology. The chapter on HIV includes current guidelines for prevention and treatment of HIV, and updates information on the new antiretroviral therapies that have become available. The chapter on immunizations contains the most recently published recommendations, discusses the contraindications and precautions relevant to special populations, and includes the new vaccines licensed since the last edition of this book. Chapters on Skin, Immunodeficiency, and Neoplastic Disease are markedly updated with the latest information. All laboratory tables in Chapter 46 Pediatric Laboratory Medicine, including Reference Ranges and Reference Intervals, have been updated. All other chapters are substantially revised and references have been updated. Nineteen new authors have contributed to these revisions.

## ACKNOWLEDGMENTS

The editors would like to thank Bonnie Savone for her expert assistance in managing the flow of manuscripts and materials among the chapter authors, editors, and publishers. Her attention to detail was enormously helpful. The editors also would like to thank Tia Brayman at Children's Hospital Colorado who produced the cover photographs.

William W. Hay, Jr., MD  
Myron J. Levin, MD  
Robin R. Deterding, MD  
Mark J. Abzug, MD

Denver, Colorado  
June 2014

# Advancing the Quality and Safety of Care

Daniel Hyman, MD, MMM



While the history of the patient safety movement can be traced back to Hippocrates' famous dictum *primum non nocere* some 2500 years ago, the more modern safety effort was galvanized by the Institute of Medicine's (IOM) 1999 landmark report *To Err Is Human*. The most quoted statistic from this report, that between 44,000 and 98,000 Americans die each year as a result of medical error, was based upon studies of hospital mortality in Colorado, Utah, and New York and extrapolated to an annual estimate for the country. The IOM followed up this report with a second publication, *Crossing the Quality Chasm*, in which they said, "Health care today harms too frequently, and routinely fails to deliver its potential benefits.... Between the health care we have and the care we could have lies not just a gap, but a chasm." These two reports have served as central elements in an advocacy movement that has engaged stakeholders across the continuum of our healthcare delivery system and changed the nature of how we think about the quality of care we provide, and receive.

In *Crossing the Quality Chasm*, the IOM included a simple but elegant definition of the word "Quality" as it applies to health care. They defined six domains of healthcare quality: (1) SAFE—free from preventable harm, (2) EFFECTIVE—optimal clinical outcomes; doing what we should do, not what we should not do according to the evidence, (3) EFFICIENT—without waste of resources—human, financial, supplies/equipment, (4) TIMELY—without unnecessary delay, (5) PATIENT/FAMILY CENTERED—according to the wishes and values of patients and their families, (6) EQUITABLE—eliminating disparities in outcomes between patients of different race, gender, and socioeconomic status.

In the years since these two reports were published, the multiple stakeholders concerned about the effectiveness, safety, and cost of health care in the United States, and indeed throughout the world, have accelerated their individual and collective involvement in analyzing and improving care. In the United States, numerous governmental agencies, large employer groups, health insurance plans, consumers/patients,

healthcare providers, and delivery systems are among the key constituencies calling for and working toward better and safer care at lower cost. Similar efforts are occurring internationally. Indeed, the concept of the Triple Aim is now being promoted as an organizing framework for considering the country's overall healthcare improvement goals.


Committee on Quality Health Care in America, Institute of Medicine: *Crossing the Quality Chasm: a New Health System for the 21st Century*. Washington, DC: National Academy Press; 2001.

Kohn L, Corrigan JM: *To Err Is Human: Building a Safer Health System*. Washington, DC: National Academy Press; 2000.

## CURRENT CONTEXT

The healthcare industry is in a period of transformation being driven by at least four converging factors: (1) the recognition of serious gaps in the safety and quality of care we provide (and receive), (2) the unsustainable increases in the cost of care as a percent of the national economy, (3) the aging of the population, and (4) the emerging role of healthcare information technology as a potential tool to improve care. These are impacting healthcare organizations as well as individual practitioners in numerous ways that can also be traced to expectations regarding transparency and increasing accountability for results. As depicted in Figure 1-1, the Triple Aim includes the simultaneous goals of better care (outcomes/experience) for individual patients, better health for the population, and lower cost overall. Practitioners and trainees must adapt to a new set of priorities that focus attention on new goals to extend our historic focus on the doctor/patient relationship and autonomous physician decision making. Instead, new imperatives are evidence-based medicine, advancing safety, and reducing unnecessary expense.

The impact of healthcare quality improvement will increasingly influence clinical practice and the delivery of pediatric



▲ **Figure 1-1.** Triple aim. (Adapted from the Center for Medicare and Medicaid Services.)

care in the future. This chapter provides a summary of some of the central elements of healthcare quality improvement and patient safety, and offers resources for the reader to obtain additional information and understanding about these topics.

To understand the external influences driving many of these changes, there are at least six key national organizations central to the transitions occurring.

1. Center for Medicare and Medicaid Services (Department of Health and Human Services)—[www.cms.gov](http://www.cms.gov)  
Center for Medicare and Medicaid Services (CMS) oversees the United States' federally funded healthcare programs including Medicare, Medicaid, and other related programs. CMS and the Veterans Affairs Divisions together now provide funding for more than one trillion of the total \$2.6 trillion the United States spends annually on healthcare expense. CMS is increasingly promoting payment mechanisms that withhold payment for the costs of preventable complications of care and giving incentives to providers for achieving better outcomes for their patients, primarily in its Medicare population. The agency has also enabled and advocated for greater transparency of results and makes available on its website comparative measures of performance for its Medicare population. CMS is also increasingly utilizing its standards under which hospitals and other healthcare provider organizations are licensed to provide care as tools to ensure greater compliance with these regulations. It has adopted a list of hospital-acquired conditions (HACs) in 10 categories for which hospitals are no longer reimbursed. This list of HACs includes for 2013: foreign object retained after surgery, air embolism, blood incompatibility, stage III and IV pressure ulcers, falls and trauma, manifestations of poor glyce-mic control, catheter-associated urinary tract infection, iatrogenic pneumothorax, vascular catheter-associated
2. National Quality Forum—[www.qualityforum.org/Home](http://www.qualityforum.org/Home)  
National Quality Forum (NQF) is a private, not-for-profit organization whose members include consumer advocacy groups, healthcare providers, accrediting bodies, employers and other purchasers of care, and research organizations. The NQF's mission is to promote improvement in the quality of American health care primarily through defining priorities for improvement, approving consensus standards and metrics for performance reporting, and through educational efforts. The NQF, for example, has endorsed a list of 29 "serious reportable events" in health care that include events related to surgical or invasive procedures, products or device failures, patient protection, care management, environmental issues, radiologic events, and potential criminal events. This list and the CMS list of HACs are both being used by insurers to reduce payment to hospitals/providers as well as to require reporting to state agencies for public review. In 2011, NQF released a set of 41 measures for the quality of pediatric care, largely representing outpatient preventive services and management of chronic conditions, and population-based measures applicable to health plans, for example immunization rates and frequency of well-child care.
3. Leapfrog—[www.leapfroggroup.org](http://www.leapfroggroup.org)  
Leapfrog is a group of large employers who seek to use their purchasing power to influence the healthcare community to achieve big "leaps" in healthcare safety and quality. Leapfrog promotes transparency and issues public reports of how well individual hospitals meet their recommended standards, including computerized physician-order entry, ICU staffing models, and rates of hospital-acquired infections. There is some evidence that meeting these standards is associated with improved hospital quality and/or mortality outcomes.
4. Agency for Healthcare Research and Quality—[www.ahrq.gov](http://www.ahrq.gov)  
Agency for Healthcare Research and Quality (AHRQ) is one of 12 agencies within the US Department of Health

infection, and surgical site infection or deep vein thrombosis/pulmonary embolism after selected procedures. It is worth noting that CMS is able to generate comparative national data only for its Medicare population because it, unlike Medicaid, is a single federal program with a single financial database. Because the Medicaid program functions as 51 state/federal partnership arrangements, patient experience and costs are captured in 51 separate state-based program databases. This segmentation has limited the development of national measures for pediatric care in both inpatient and ambulatory settings. Similarly, while the reporting of HACs is uniform across the United States for Medicare patients, in the Medicaid population it varies by individual state.

and Human Services. AHRQ's primary mission has been to support health services research initiatives that seek to improve the quality of health care in the United States. Its activities extend well beyond the support of research and now include the development of measurements of quality and patient safety, reports on disparities in performance, measures of patient safety culture in organizations, and promotion of tools to improve care among others. AHRQ also convenes expert panels to assess national efforts to advance quality and patient safety and to recommend strategies to accelerate progress.

5. Specialty Society Boards  
Specialty Society Boards, for example, American Board of Pediatrics (ABP). The ABP, along with other specialty certification organizations, has responded to the call for greater accountability to consumers by enhancing its maintenance of certification programs (MOC). All trainees, and an increasing proportion of active practitioners, are now subject to the requirements of the MOC program, including participation in quality improvement activities in the diplomate's clinical practice. The Board's mission is focused on assuring the public that certificate holders have been trained according to their standards and also meet continuous evaluation requirements in six areas of core competency: patient care, medical knowledge, practice-based learning and improvement, interpersonal and communication skills, professionalism, and systems-based practice. These are the same competencies as required of residents in training programs as certified by the Accreditation Council on Graduate Medical Education. Providers need not only to be familiar with the principles of quality improvement and patient safety, but also must demonstrate having implemented quality improvement efforts within their practice settings.
6. The Joint Commission—[www.jointcommission.org](http://www.jointcommission.org)  
The Joint Commission (JC) is a private, nonprofit agency that is licensed to accredit healthcare provider organizations, including hospitals, nursing homes, and other healthcare provider entities in the United States as well as internationally. Its mission is to continuously improve the quality of care through evaluation, education, and enforcement of regulatory standards. Since 2003, JC has annually adopted a set of National Patient Safety Goals designed to help advance the safety of care provided in all healthcare settings. Examples include the use of two patient identifiers to reduce the risk of care being provided to an unintended patient; the use of time-outs and a universal protocol to improve surgical safety and reduce the risk of wrong site procedures; adherence to hand hygiene recommendations to reduce the risk of spreading hospital-acquired infections, to name just a few. These goals often become regulatory

standards with time and widespread adoption. Failure to meet these standards can result in actions against the licensure of the healthcare provider, or more commonly, requires corrective action plans, measurement to demonstrate improvement, and resurveying depending upon the severity of findings. The JC publishes a monthly journal on quality and safety, available at <http://store.jcrinc.com/the-joint-commission-journal-on-quality-and-patient-safety/>.

Finally, advances in quality and safety will be impacted by the provisions of the American Recovery and Reinvestment Act (ARRA) and Patient Protection and Affordable Care Act (PPACA) enacted by the United States government in the past 2 years. These laws and their implications are only beginning to be understood in the United States. The landmark 2010 federal healthcare legislation will provide for near-universal access to health care, and now that the Supreme Court has upheld the law, states are beginning the process of creating healthcare exchanges or deferring to the federal government to do so. It is likely that changes in payment mechanisms for health care will continue irrespective of ARRA/PPACA, and current and future providers' practices will be economically, structurally, and functionally impacted by these emerging trends. Furthermore, changes in the funding and structure of the US healthcare system may ultimately also result in changes in other countries. Many countries have single-payer systems for providing health care to their citizens and often are leaders in defining new strategies for healthcare improvement.

Agency for Healthcare Research and Quality: [www.ahrq.gov](http://www.ahrq.gov).  
 American Board of Pediatrics. <https://www.abp.org>. Accessed 12/25/12.  
 Berwick D, Nolan T, Whittington J: The triple aim: Care, health, and cost. doi 10.1377/hlthaff.27.3.759 *Health Affairs* 2008;27(3): 759-769.  
 Center for Medicare and Medicaid Services: Triple Aim.  
 Center for Medicare and Medicaid Services: [www.cms.gov](http://www.cms.gov).  
 CMS list of Hospital-Acquired Conditions.  
 Connors E, Gostin L: Health Care Reform—A Historic Moment in US Social Policy. doi: 10.1001/jama.2010.856. *JAMA* 2010; 303(24):2521-2522.  
 Hawkins RE, Weiss KB: Commentary: *Building the Evidence Base in Support of the American Board of Medical Specialties Maintenance of Certification Program*. doi: 10.1097/ACM.0b013e318201801b. *Academic Medicine* 2011;86(1):6-7.  
<http://www.nejm.org/doi/full/10.1056/NEJMp0804658>. Accessed 12/25/12.  
[http://www.qualityforum.org/News\\_And\\_Resources/Press\\_Releases/2011/NQF\\_Releases\\_Updated\\_Child\\_Quality\\_Health\\_Measures.aspx](http://www.qualityforum.org/News_And_Resources/Press_Releases/2011/NQF_Releases_Updated_Child_Quality_Health_Measures.aspx). Accessed 12/25/12. (Reference on 41 NQF pediatric measures).  
[http://www.qualityforum.org/News\\_And\\_Resources/Press\\_Releases/2011/NQF\\_Endorses\\_Child\\_Health\\_Outcome\\_Measures.aspx](http://www.qualityforum.org/News_And_Resources/Press_Releases/2011/NQF_Endorses_Child_Health_Outcome_Measures.aspx). Accessed 12/25/12.



[http://www.qualityforum.org/Topics/SREs/List\\_of\\_SREs.aspx](http://www.qualityforum.org/Topics/SREs/List_of_SREs.aspx). Accessed 12/25/12. (NQF 29 serious reported events list).

[https://www.cms.gov/nationalhealthexpenddata/02\\_national-healthaccountshistorical.asp](https://www.cms.gov/nationalhealthexpenddata/02_national-healthaccountshistorical.asp). Accessed 9/21/11. (Reference on federal healthcare spending).

Jha A, Oray J, Ridgway A, Zheng J, Epstein A: Does the Leapfrog Program help identify high-quality hospitals? *The Joint Commission Journal on Quality and Patient Safety* 2008;34(6): 318-325.

Leapfrog: [www.leapfroggroup.org](http://www.leapfroggroup.org).

Miller T, Leatherman S: The National Quality Forum: a 'me-too' or a breakthrough in quality measurement and reporting? *Health Affairs* 1999;18(6):233-237.

Rosenthal M, Engi N: Beyond pay for performance—emerging models of provider-payment. *Reform Med* 2008;359:1197-1200.

Shekelle P, Pronovost P, Wachter R et al: Advancing the science of patient safety. *Annals of Internal Medicine* 2011;154(10):693-696.

Straube B, Blum JD: The policy on paying for treating hospital-acquired conditions: CMS officials respond. *Health Affairs* 2009;28(5):1494-1497.

The Joint Commission. [www.jointcommission.org](http://www.jointcommission.org). <http://store.jcrinc.com/the-joint-commission-journal-on-quality-and-patient-safety/>.

## STRATEGIES AND MODELS FOR QUALITY IMPROVEMENT (QI)

There are a number of commonly employed approaches to improving the quality of care in healthcare settings. This section highlights three representative approaches to conducting clinical improvement work, but they are by no means the only potential strategies that physicians and staff may see or utilize. The Model for Improvement is primarily emphasized because of its ease of adoption, and because it is the foundation for most improvement efforts included in the Maintenance of Certification program of the American Board of Pediatrics. Briefer summaries of Lean and Six-Sigma methods are also included, with listings of resources where the reader can find additional information.


### “MODEL FOR IMPROVEMENT”

Widely taught and promoted by the Boston-based educational and advocacy organization the Institute for Healthcare Improvement (IHI), the Model for Improvement (MFI) is grounded in three simple questions that guide the work of the improvement leader and team. The model's framework includes an Aim statement, a measurement strategy, and then the use of “rapid cycle” changes to achieve the aim. The IHI web site, [www.ihl.org](http://www.ihl.org), has an extensive resource library, and hosts an “Open School” that includes a QI/Patient safety modular curriculum for health professional students and their faculty at [www.ihl.org/openschool](http://www.ihl.org/openschool).

### AIM STATEMENT

The Aim statement answers the question, “What do we want to accomplish?” The measure question is “How will we know

### Model for improvement



▲ **Figure 1-2.** Model for improvement. (Adapted, with permission, from G. Langley, R. Moen, K. Nolan, T. Nolan, C. Norman, L. Provost: *The Improvement Guide: AIM model for Improvement*. San Francisco, CA: Jossey-Bass; 2009:24.)

that a change is an improvement?” and the change component is focused on “What changes can we make that will result in improvement?” This model is represented in Figure 1-2.

Aim statements are a *written* description of what the team's improvement goal is, and also include information on who comprises the patient population and a time frame within which the improvement will be achieved. They identify a “stretch” but achievable improvement target goal, and, often, some general statement regarding how the improvement will be achieved. Aim statements are sometimes characterized using the mnemonic SMAART: Specific, Measurable, Achievable, Actionable, Relevant, and Timely. Aim statements should be unambiguous and understandable to the stakeholders, and are most likely to be achieved if they are aligned with the strategic goals of the team or organization.

For example, the following statement meets the criteria for a SMAART aim statement, “*We will reduce the frequency of emergency department visits and hospitalizations for patients with asthma seen at E Street Pediatrics by 25% by December 31, 2013.*” Whereas, this next statement does not, “*We will improve the care for patients with asthma by appropriately prescribing indicated medications and better educating families in their use.*”

The first example provides a specific measurable goal, a time frame, and clarity with respect to who the patients are. A 25% reduction in ED/inpatient asthma visits will require a change in the system for asthma care delivery for the entire population of children with asthma; that extent of level of improvement is a stretch, but it is much more achievable than a goal would be if it was set to “eliminate” such encounters. The second example is unclear in terms of the measure for improvement, the time frame for the goal to be met, and even the population in question. The statement provides some sense of processes that could be utilized to improve asthma care but is missing needed specificity.

## MEASURES

Specific measures provide a means to assess whether or not the improvement effort is on track. Three types of measures are useful. *Outcome measures* answer questions concerning the healthcare impact for the patients, such as how has their health status changed? *Process measures* are related to the healthcare delivery system itself. They answer questions like how is the system performing? *Balancing measures* seek to identify potential unintended consequences that are related to the improvement effort being undertaken. Examples are helpful to contextualize these conceptual definitions.

Continuing with asthma as an example of the improvement effort, and utilizing the first aim statement example, here are some examples of measures that might be employed, and the type of measure each is.

Examples of measures for an asthma improvement project:

1. Proportion of children with an asthma severity assessment in their medical record in the past year (process).
2. Percent of children with asthma in the practice seen in the ED or hospitalized for asthma in the past 6 months (outcome).
3. Average difference in the time between the last office patient's scheduled appointment time and the actual office close time (balancing).
4. Staff satisfaction with their job (balancing).
5. Percent of children with persistent asthma, of any severity, prescribed a controller medication at their most recent visit (process).
6. Percent of children prescribed a controller medication who report taking their medicine (process—this one might seem surprising, but an outcome measures the health status of the patient, not the taking of a medication. One might argue that adherence to a treatment plan is an outcome of the work of the practice/practitioner prescribing the medication. It is more consistent, however, to consider the translation of the treatment plan into action as a part of the process of care, and that the health status or outcome measure will be improved by fully improving the measured processes of care, including patient adherence to the treatment plan.)
7. Percent of children in a practice asthma registry provided with a complete asthma action plan in the past twelve months (process).
8. Percent of children who missed any school days due to asthma in the past 6 months (outcome).

Measures are essential elements of any improvement work. It is a good idea to choose a manageable (4–6) number of measures, all of which can be obtained with limited or no extra

effort, and with a mix of outcome, process, and balancing measures. Ideally, the best process measures are those that are directly linked to the outcome goal. The hypothesis in this specific example would be that assessing asthma severity and appropriately using controller medications and action plans would all contribute to reducing the number or frequency of missed school days and the need for ED/hospital utilization.

It is important to note that measurement in the setting of an improvement project is different from measurement in a research study. Improvement projects require “just enough” data to guide the team’s continuing efforts. Often the results seen in a sequence of 10 patients is enough to tell you whether a particular system is functioning consistently or not. For example, considering measure example number 1, if in the last 10 patients seen with asthma, only two had their asthma severity documented, how many more charts need be checked to conclude that the system is not functioning as intended and that changes are needed? Other measures may require larger sample sizes, especially when assessing the impact of care changes on a population of patients with a particular condition. See Randolph’s excellent summary for a fuller description of measurement for improvement.

## CHANGES AND IDEAS

Once the team’s aim is established and the measures are selected, the third component of the Model for Improvement focuses on what changes in the system must be made that will result in the targeted improvements. Here, the model draws from the field of industrial engineering and the work of improvement pioneers W. Edwards Deming and Walter Shewhart. To answer the question “What changes will result in improvement?”, the improvement team should incorporate “Plan-Do-Study (or check)-Act” cycles, typically referred to as PDSA cycles. The cycles include the following steps.

*Plan:* What will we do that will likely improve the process measures linked to the outcome target goal? Who will do it? Where? When? How? How will the data be collected?

*Do:* Implementation of the planned change(s). *TIP!* It is good to make the change cycles as small as possible, for example, trying a new process on the next five patients being seen by one provider as opposed to wide scale implementation of a new chart documentation form across an entire clinic.

*Study (or check):* Once the small test of change is tried, its results are assessed. How many times did the process work as planned for the five patients included in the cycle?

*Act:* Based upon the results of the study of the cycle, recommendations are made as to what the next steps ought to be to achieve the goal. At this point, the cycle then resumes and planning begins for the next cycle.

Over the course of an improvement effort, multiple tests of change might be implemented for any or all of the process measures felt to be likely to impact the outcome measures relevant to the project.

The Model for Improvement has been used by improvement teams across numerous healthcare settings around the world. Further information about the model and examples can be found at [www.ihl.org/openschool](http://www.ihl.org/openschool), or in *The Improvement Guide* (Langley et al).

The IHI Open School modules are an excellent online resource for clinicians interested in learning more about the fundamentals of quality improvement and patient safety. These educational lessons are free of charge to health professional students, residents, and university faculty members, and for a modest subscription fee to other clinicians. They are also free to healthcare practitioners in the developing world. An excellent original resource on implementing this model in clinical practice is in Berwick's summary article from 1998.

Berwick D: The science of improvement. *JAMA* 2008;299(10):1182–1184.

Langley G, Moen R, Nolan K, Nolan T, Norman C, Provost L: *The Improvement Guide: AIM model for Improvement*. San Francisco, CA: Jossey-Bass; 2009:24.

Randolph G, Esporas M, Provost L, Massie S, Bundy D: Model for Improvement Part Two: *Measurement and Feedback for Quality Improvement Efforts*. *Ped Clin N Am* 2009;56(4):779–798; Developing and Testing Changes in Delivery of Care Berwick, Donald M. MD, MPP. This paper is also available at <http://www.acponline.org>. *Ann Intern Med* 1998;128:651–656.

## “LEAN”

Also grounded in industrial engineering, an increasingly popular method for driving improvement efforts in healthcare settings is “Lean” or “Lean processing.” Early thinking about Lean processes is credited to the Toyota Manufacturing Company in Japan. The crossover to health care from manufacturing is a relatively recent phenomenon, but numerous hospitals and healthcare delivery settings, including individual clinics, have benefited from the application of these principles to their clinical operations. Lean improvement methods focus on reducing errors and variability in repetitive steps that are part of any process. In health care, examples of repeated processes would include how patients are registered and their information obtained; how medications are ordered, compounded, distributed, and administered; how consent forms are accurately completed in a timely manner prior to surgical procedures; and how antibiotics are reliably and efficiently delivered prior to surgical procedures.

Lean is a philosophy of continuous improvement. It is grounded in recognizing that the way we do things today is merely “current state.” With time, effort, focus, and long-term thinking, we can create a “future state” that is better than the status quo. It does so by focusing on identifying the value of all steps in any process and eliminating those steps

that do not contribute to the value sought by the customer, or in health care, the patient/family. In doing so, improvements in outcomes, including cost and productivity, and in clinical measures of effectiveness can be realized. See Young for an early critical assessment of the incorporation of Lean into healthcare settings.

There are four categories that describe the essential elements of Toyota's adoption of “Lean” as a management strategy. These four categories are: (1) *philosophy* (emphasize long-term thinking over short-term gain); (2) *process* (eliminate waste through very defined approaches including an emphasis on process flow and the use of pull systems to reduce overproduction, for example); (3) *people/partners* (respect, challenge, and grow staff); and (4) *problem solving* (create a culture of continuous learning and improvement).

There are a number of hospitals that have fully integrated Lean management as a primary basis for its organizational approach to improvement. Several were featured in a “White Paper” published by the Institute for Healthcare Improvement in 2005.

Going Lean in Health Care, Innovation Series White Paper. Institute for Healthcare Improvement; 2005. <http://www.ihl.org/knowledge/Pages/IHIWhitePapers/GoingLeaninHealthCare.aspx>.

Liker: *The Toyota Way*. Madison, WI: McGraw-Hill; 2004.

Young TP, McClean SI: A critical look at Lean Thinking in health care. *BMJ Quality and Safety Health Care* 2008;17:382–386.

## “SIX SIGMA”

A third quality-improvement methodology also arose in the manufacturing industry. Motorola is generally credited with promoting Six Sigma as a management strategy designed to reduce the variability in its processes and thereby reducing the number of defects in its outputs. Organizations adopting Six Sigma as an improvement strategy utilize measurement-based strategies that focus on process improvement and variation reduction to eliminate defects in their work and to reduce cycle times, thereby increasing profitability and enhancing customer satisfaction. Sigma is the statistical measure of standard deviation and Motorola adopted Six Sigma as a performance indicator, promoting consistency of processes in order to have fewer than 3.4 defects per million opportunities. This performance goal has since become the common descriptor for this approach to improvement both in manufacturing and in service industries, including health care. Similar to Lean, the translation of business manufacturing strategies into health care has various challenges, but there are many processes that repeatedly occur in health care that can be routinized and made more consistent. Many healthcare processes fail far more frequently than 3.4 times per million opportunities. Consider pharmacy dispensing errors, medication ordering or administration errors, and patient-scheduling errors,

just to name a few. These are a few of many examples of processes that could potentially benefit from the kind of rigorous analysis that is integral to the Six-Sigma approach.

In a typical Six-Sigma structured improvement project, there are five phases generally referred to as DMAIC: (1) Define (what is the problem, what is the goal?), (2) Measure (quantify the problem and improvement opportunity), (3) Analyze (use of observations and data to identify causes), (4) Improve (implementation of solutions based on data analysis), and finally, (5) Control (sustainable change).

One of the central aspects of Six Sigma as an improvement strategy is its defined focus on understanding the reasons for defects in any process. By understanding these drivers, it is then possible to revise the approach to either the manufacturing process or the service functions in order to reduce these errors and failures.

“Lean-Six Sigma” is a newer entity that draws from both methodologies in order to simplify the improvement work where possible, but retain the rigorous statistical method that is a hallmark of Six-Sigma projects. Lean focuses on where time is lost in any process and can identify opportunities to eliminate steps or reduce time. Six Sigma aims to reduce or eliminate defects in the process, thereby resulting in a higher-quality product through a more efficient and lower cost process.

Regardless of the method used, improvement happens because an organization, team, or individual sets a goal to improve a current process through systematic analysis of the way things are done now, and then implementing planned changes to see how they impact the outputs or outcomes.

For additional information on Lean and Six Sigma, see [www.isixsigma.com](http://www.isixsigma.com) or [www.asq.org/sixsigma](http://www.asq.org/sixsigma).

Pande P, Holpp L: *What is Six Sigma?* New York, NY: McGraw-Hill; 2002.

## PRINCIPLES OF PATIENT SAFETY (INCIDENT REPORTING, JUST CULTURE, DISCLOSURE, FMEA, RCA, RELIABILITY, CHECKLISTS)

Safe patient care avoids preventable harm; it is care that does not cause harm as it seeks to cure. The list of adverse events that are considered to be preventable is evolving. As mentioned earlier, both CMS and NQF have endorsed lists of various complications of care as being “never events” or “serious reportable events” for which providers are often now not reimbursed, and which are increasingly reportable to the public through various state transparency programs.

Irrespective of one’s views about whether various complications are entirely preventable at the current state of science or not, these approaches reflect a changing paradigm that is impacting many aspects of healthcare delivery. Transparency of results is increasingly expected. Perspectives and data on

how these kinds of efforts are impacting actual improvement in outcomes are mixed.

Given these trends, healthcare providers need to have robust systems for measuring and improving the safety of care provided to patients. The methods for improving quality reviewed above are frequently used to reduce harm, just as they can be used to improve effectiveness or efficiency. For example, hospitals attempting to reduce infections have successfully used these types of process improvement approaches to improve antibiotic use prior to surgical procedures or to improve hand hygiene practices.

Common patient safety tools are summarized here.

*Incident-reporting systems:* Efforts to advance safety in any organization require a clear understanding of the kinds of harm occurring within that organization, as well as the kinds of “near-misses” that are occurring. These reporting systems can range from a simple paper reporting form to a “telephone hot-line” to a computerized database that is available to staff (and potentially patients) within the organization. Events are traditionally graded according to the severity of harm that resulted from the incident. One example is the NCC MERP Index, which grades events from A (potential to cause harm) to I (resulting in patient death). Errors that are recognized represent only a fraction of the actual errors and near-misses that are present in the system. Incident-reporting systems depend upon people recognizing the error or near-miss, being comfortable reporting it, knowing how and when to report, and then actually doing so. It is no surprise therefore that estimates for how frequently incidents that could or should be reported into incident-reporting systems range from 1.5% to 30% depending on the type of adverse or near-miss event. “Trigger tools” (either manual chart reviews for indications of adverse events, or automated reports from electronic medical records) are increasingly being used to increase the recognition of episodes of harm in healthcare settings.

*“Just culture”:* The effectiveness of incident-reporting systems is highly dependent upon the culture of the organization within which the reporting is occurring. Aviation industry safety-reporting systems are often highlighted for their successes over the past few decades in promoting reporting of aviation events that might have led to accidents. The Aviation Safety Reporting System (ASRS) prioritizes confidentiality in order to encourage reporting and protects reporters from punishment, with certain limitations when they report incidents, even if related to nonadherence to aviation regulations. Although the system is voluntary, more than 880,000 reports have been submitted and used by the Federal Aviation Administration to improve air travel safety.

In health care, the variable recognition of adverse events as well as any fear about reprisal for reporting events both work to reduce the consistent reporting of events. The concept of “just culture” has been promoted as a strategy to increase the comfort of staff members to report the occurrence of errors

or near-misses, even if they may have done something incorrectly. See the work of David Marx and the “Just Culture Community” for more information on how to evaluate error so as to support reporting and safer practices in organizations. A great deal more information about “just culture” principles is available at <http://www.justculture.org>.

**Failure modes and effects analyses (FMEA):** An FMEA is a systematic methodology used to proactively identify ways in which any process might fail, and then to prioritize among strategies for reducing the risk or impact of identified potential failures. In conducting an FMEA, which all hospitals are required to do annually, a team will carefully describe and analyze each step in a particular process, consider what and how anything might go wrong, why it would happen and what the impact would be of such failures. Like Lean and Six Sigma, the FMEA has been adopted into health care from its origins in military and industrial settings. The FMEA is an effective method for identifying strategies to reduce risks in healthcare settings, thereby protecting patients if interventions are put into place as a result of the analysis. A tool to use in conducting an FMEA is available from the IHI (<http://www.ihl.org/knowledge/Pages/Tools/FailureModesandEffectsAnalysisTool.aspx>). Their site includes additional information and resources about the FMEA process.

**Root-cause analyses (RCA) (post-event reviews):** As contrasted with the proactive FMEA process, an RCA is a retrospective analysis of an adverse occurrence (or near-miss) that has already happened. It too is a systematic process that in this case allows a team to reach an understanding of why certain things occurred, what systems factors and human factors contributed to the occurrence, and what defects in the system might be changed in order to reduce the likelihood of recurrence. Key to an effective RCA process, and similar to the principles discussed above related to “just culture,” RCAs are designed not to ask who was at fault, but rather what system reasons contributed to the event. “Why,” not “who,” is the essential question to be asked. The answer to the question “why did this occur” almost invariably results in a combination of factors, often illustrated by a series of pieces of Swiss cheese where the holes all line up. Taken from the writings of James Reason, the “Swiss Cheese Model” illustrates the many possible system failures that can contribute to an error, and contributes to identifying potential system changes that reduce the risk of error recurrence. Strategies for approaching retrospective RCA are available at <http://www.ncbi.nlm.nih.gov/pmc/articles/pmc1117770>.

**Communication and team training:** Because failures of communication are the most common identified factors in the analysis of reported serious healthcare events, many

healthcare organizations have incorporated tools from other industries, particularly aviation, in order to enhance patient safety. As a result of the knowledge gained through analysis of tragic aviation accidents, the airline industry implemented methods like crew resource management training to ensure that communication among cockpit team members is effective and clear, thereby reducing risk of air accidents. Similar methods have been used to train teams in operating rooms, delivery rooms, and other team-based settings. Most of these curricula include a few common elements: introductions to be sure all team members know one another’s name, promoting the likelihood of speaking up; leader clarity with team members about the expectation that all will speak up if anyone has a concern; and structured language and other tools like verbal read-back of critical information to ensure clarity in interpersonal or interdisciplinary communications. Such training also seeks to flatten the hierarchy, making it more likely that potential risks or problems will be identified and effectively addressed. Common tools used in promoting effective team communication include structured language like SBAR (Situation, Background, Assessment, and Recommendation), taken from the navy, to promote clarity of communication.

A number of resources exist in the public domain to support better teamwork and communication. One good place to start is the TeamSTEPPS program from the Agency for Healthcare Research and Quality. It can be found at <http://teamstepps.ahrq.gov/>.

Ashley L, Armitage G, Neary M, Hoolingsworth G: *A Practical Guide to Failure Mode and Effects Analysis in Health Care: Making the Most of the team and its meetings*. Joint Commission Journal on Quality and Patient Safety 2010;36(8):351–358. <http://www.ihl.org/knowledge/Pages/Tools/FailureModesandEffectsAnalysisTool.aspx>.

[http://www.mers-tm.org/support/Marx\\_Primer.pdf](http://www.mers-tm.org/support/Marx_Primer.pdf): 2001.

[http://www.qualityforum.org/News\\_And\\_Resources/Press\\_Releases/2011/NQF\\_Releases\\_Updated\\_Serious\\_Reportable\\_Events.aspx](http://www.qualityforum.org/News_And_Resources/Press_Releases/2011/NQF_Releases_Updated_Serious_Reportable_Events.aspx). Accessed 9/21/11. (Reference on 29 serious reportable events NQF).

Incident Reporting Systems: <http://www.nccmerp.org/>.

Marx D: *A Primer for Health Care Executives: Patient Safety and the “Just Culture.”* New York, NY: Columbia University.

Mills R: *Collaborating With Industry to Ensure Regulatory Oversight: The Use of Voluntary Safety Reporting Programs by the Federal Aviation Administration* [dissertation]. Kent State University, College of Arts and Sciences, 2011. [http://etd.ohiolink.edu/view.cgi?acc\\_num=kent1302102713](http://etd.ohiolink.edu/view.cgi?acc_num=kent1302102713). Accessed 12/25/12.

Reason J: Human error: models and management. *BMJ* 320:768. doi: 10.1136/bmj.320.7237.768:2000.

Shekelle P, Pronovost P, Wachter R et al: Advancing the science of patient safety. 2011;154(10):693–696.

# The Newborn Infant

Adam A. Rosenberg, MD  
Theresa Grover, MD

## 2

The newborn period is defined as the first 28 days of life. In practice, however, sick or very immature infants may require neonatal care for many months. There are three levels of newborn care. Level 1 refers to basic care of well newborns of 35 weeks' gestation or more, neonatal resuscitation, and stabilization prior to transport. Level 2 refers to specialty neonatal care of premature infants greater than 1500 g or more than 32 weeks' gestation. Level 3 is subspecialty care of higher complexity ranging from 3A to 3D based on newborn size and gestational age, availability of medical subspecialties, advanced imaging, pediatric ophthalmology, pediatric general surgery, cardiac surgery, and extracorporeal membrane oxygenation. Level 3 care is often part of a perinatal center offering critical care and transport to the high-risk mother and fetus as well as the newborn infant. A level 4 center has additional capabilities to care for complex surgical conditions including cardiac surgery with bypass.

### THE NEONATAL HISTORY

The newborn medical history has three key components:

1. Maternal and paternal medical and genetic history
2. Maternal past obstetric history
3. Current antepartum and intrapartum obstetric history

The mother's medical history includes chronic medical conditions, medications taken during pregnancy, unusual dietary habits, smoking history, occupational exposure to chemicals or infections of potential risk to the fetus, and any social history that might increase the risk for parenting problems and child abuse. Family illnesses and a history of congenital anomalies with genetic implications should be sought. The past obstetric history includes maternal age, gravidity, parity, blood type, and pregnancy outcomes. The current obstetric history includes the results of procedures during the current pregnancy such as ultrasound, amniocentesis, screening tests (rubella antibody, hepatitis B surface antigen, serum quadruple screen in the second trimester or first trimester ultrasound screening for nuchal translucency coupled with measurement in maternal serum

of human chorionic gonadotropin and pregnancy-associated plasma protein A to screen for genetic disorders, HIV [human immunodeficiency virus], and antepartum tests of fetal well-being (eg, biophysical profiles, nonstress tests, or Doppler assessment of fetal blood flow patterns). Pregnancy-related maternal complications such as urinary tract infection, pregnancy-induced hypertension, eclampsia, gestational diabetes, vaginal bleeding, and preterm labor should be documented. Significant peripartum events include duration of ruptured membranes, maternal fever, fetal distress, meconium-stained amniotic fluid, type of delivery (vaginal or cesarean section), anesthesia and analgesia used, reason for operative or forceps delivery, infant status at birth, resuscitative measures, and Apgar scores.

### ASSESSMENT OF GROWTH & GESTATIONAL AGE

It is important to know the infant's gestational age because normal behavior and possible medical problems can be predicted on this basis. The date of the last menstrual period is the best indicator of gestational age, if known, and if menses were regular. Fetal ultrasound provides supporting information. Postnatal physical characteristics and neurologic development are also clues to gestational age. Table 2-1 lists the physical and neurologic criteria of maturity used to estimate gestational age by the Ballard method. Adding the scores assigned to each neonatal physical and neuromuscular sign yields a score corresponding to gestational age.

Disappearance of the anterior vascular capsule of the lens is also helpful in determining gestational age. Until 27-28 weeks' gestation, the lens capsule is covered by vessels; by 34 weeks, this vascular plexus is completely atrophied. Foot length, from the heel to the tip of the longest toe, also correlates with gestational age in appropriately grown infants. The foot measures 4.5 cm at 25 weeks' gestation and increases 0.25 cm/wk until term.

If the physical examination indicates a gestational age within 2 weeks of that predicted by the obstetric dates, the gestational age is as assigned by the obstetric dating. Birth weight and gestational age are plotted on standard grids (Figure 2-1) to determine whether the birth weight is